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1. INTRODUCTION
 
1.1 THE INTEREST OF THE BIOMEDICAL COMMUNITY IN THE SPACE ENVIRONMENT
 
The biomedical community became interested in utilizing the space environment
 
from two different directions. One was spacecraft system engineering
 
which has traditionally involved obtaining desired outcomes in space despite
 
an alien environment. The effects of the space environment became so
 
interesting that ideas began emerging for ways to exploit it, including
 
the processing of biological materials. The other came from within the
 
biomedical community with its effort to manipulate biological materials in
 
an environment that may be more optimum for certain processes than that
 
found on the surface of the earth.
 
Natural space environment properties include the following:
 
1. Convection-free micro-gravity environment
 
2. Ready availability of vacuum
 
3. Solar and cosmic radiation unattenuated by the atmosphere of the earth
 
4. Oxygen-free atmosphere.
 
Of these properties, virtual weightlessness is the most valuable to bioprocessinf
 
as it cannot, as yet, be duplicated on earth for more than a few seconds.
 
Examination of the attributes of weightlessness to bioprocessing will be made.
 
Advances in many areas of biomedical science are currently restrained by an
 
inability to separate, definitively, biological materials that are closely
 
related in physical properties but varying by physiological or biochemical
 
characteristics. Electrokinetic phenomena (i.e., electrophoresis,
 
sedimentation potentials, electroosmosis, and streaming potentials) are but
 
a few of the physical properties of biological material upon which separation
 
techniques have been developed.1 Electrophoresis is now widely used both as
 
an analytical and preparative method in the laboratory and as a diagnostic tool
 
in medicine. It is doubtful that the full potential of electrophoretic
 
separation has been realized. Improvements in both resolution and quantity of
 
separates can be anticipated.
 
IA list of references is provided, beginning on p. 62.
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Electrophoresis is defined as the transport of electrically charged particles
 
in aqueous media, under the influence of a direct current electrical field.
2
 
Most materials when dissolved in a given aqueous medium acquire a characteristic
 
electrical charge, and their migration velocity per unit electric field
 
(defined as the electrophoretic mobility of the substance) is thus fixed.
 
The particles may be simple ions, complex biological macromolecules and
 
colloids, or even particulate matter - either living cells, such as bacteria
 
or erythrocytes, or inert material, such as oil emulsion droplets and clay.
 
Because of its unique resolving ability, electrophoresis is most often used
 
for separation of proteins in biological fluids, with three primary purposes:
3
 
1. 	Identification of a particular molecular species
 
2. 	Quantitative analysis of each species in a mixture
 
3. 	Actual preparative separation of isolated fractions.
 
Originally, electrophoresis was carried out in free solutions but itwas soon
 
recognized that problems arise due to convective disturbances in the bulk of
 
Several major causes of these disturbances can be categorized:4
 fluid. 

a. 	The solute to be separated, if present insignificant concentration, adds
 
to the density of the supporting electrolyte. This difference in density
 
between solution and pure solvent causes gravity-caused convective flow,
 
unless means are found to prevent it.
 
b. 	Insome instances the particles may be sufficiently large to sediment
 
noticeably. While there are techniques which utilize differential
 
sedimentation to accomplish meaningful separations, within the context
 
of electrophoresis such sedimentation is usually undesirable.
 
c. 	The passage of electric current causes heating of the solution. As the
 
vessels are externally cooled, a radial temperature gradient arises,
 
again causing gravity-conditioned convection.
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d. 	The electric charge exhibited by the vessel walls within which
 
electrophoresis is carried out causes an electroosmotic streaming of
 
the fluid. This disturbance is independent of gravity and is a
 
consequence of the electrical properties of the system as a whole.
 
As defined above, electrophoresis is a separation process occuring within the
 
bulk of the liquid phase (and not at the electrodes) and based on the differences
 
in electrical transport rates. Electrophoresis alone, however, does not
 
provide for the ultimate separation of various molecular species of proteins
 
present, as their characteristic mobilities may be overlapping. Highest
 
resolution is obtained if a second separation parameter is employed by
 
introducing an element of discontinuity into the liquid phase. 5 Two methods
 
are most often used. In high density gel electrophoresis an element of
 
molecular sieving is superimposed on the electrical separation process by
 
progressively increasing the density of the supporting gel matrix. A protein
 
sample is introduced in a narrow zone at the top of two gel columns, and
 
through the combined effects of differential electrical transport and sieving
 
the proteins separated into individual zones along the length of the columns.
 
They 	can be recovered, in minute quantities only, through sectioning or
 
elution of the gel. In isoelectric focusing, a continuous pH gradient is
 
established and the proteins become immobilized at the pH corresponding to
 
their characteristic isoelectric point (mobility of proteins is pH dependent
 
the narrow pH zone of zero mobility is the isoelectric point). The separation
 
obtainable by isoelectric focusing is comparable to that in high density gels,
 
and should be contrasted with ordinary electrophoresis where, at best, only
 
six fractions are detectable in serum.
 
Two shortcomings of terrestrial electrophoresis are obvious:
6
 
1. 	While electrophoresis is excellent for analytical purposes, it has failed
 
as a preparative tool and only minute quantities can be actually
 
separated. There are no theoretical reasons why electrophoresis could
 
not be used on as broad an industrial scale as some of the other
 
4 
electrically driven processes such as electrolysis, electrocoating, etc.
 
Two major problems prevent scaling of the equipment to industrial
 
proportions: necessity of heat dissipation and difficulty of uniform
 
packing of anticonvective supporting media.
 
2. 	None of the above described anticonvective means is readily applicable
 
to separation of living cells and other particulate matter. Best
 
results are achieved with stabilization of liquids inthin films, but
 
the apparatus has low throughputs and lacks high resolution.
 
There is a widely held belief that many desirable biological separations,
 
especially of cellular components, would be possible, if convective turbulence
 
and sedimentation could be eliminated. The micro-gravity environment of
 
space should provide the proper environment for electrophorectic separation
 
of cells. Itcan be envisaged that space electrophoresis may result in a
 
significant broadening of the scope of applications of this separation
 
technique - inmicro-gravity increased purity (factor 5-10 in resolution) is
 
expected as well as higher throughput.
 
1.2 	 SPACE BIOPROCESSING EXPERIENCE TO DATE
 
The idea of using space flight to stabilize liquid media for electrophoretic
 
separation was proposed late in1969 for the NASA Materials Sciences
 
Manufacturing inSpace (MS/MS) program.7 Following analytical studies and
 
advice from the scientific community, the first electrophoresis experiment
 
at zero gravity was carried out on the return trip from the moon on Apollo
 
14, with an attempted separation of red and blue dyes. Photographic records
 
showed that the separation of the dyes was sharper than was possible with
 
comparable equipment on earth. Itwas also demonstrated that the component
 
parts of the apparatus worked as designed.
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A second zero gravity experiment was conducted on Apollo 16 using the basic
 
operating elements of the Apollo 14 unit for the electrophoresis of
 
polystyrene latex.8 These stable, nondegradable particles were used as a
 
model for living cells. Two sizes of latex particles were run separately
 
and together in order to provide comparative data. During the experiment
 
itself, the sample bands were severely distorted by electroosmosis which
 
caused buffer flow along the walls of the columns counter to the direction
 
of electrophoretic migration of the latex particles.
 
For the Apollo-Soyez Test Program, plans were to use parts of the Apollo 14
 
and Apollo 16 systems that operated correctly, improve the techniques that
 
proved faulty and add an isotachophoresis segment to the experiment. The
 
Apollo-Soyez electrophoresis experiment MA-0ll was rewarding, as the
 
following paragraph from the MA-Oll preliminary report indicates:
9
 
"With the successful separation of the standard particles (fixed red blood
 
cells) and the human kidney cells there is no longer a question of
 
electrophoretic possibilities in zero gravity. The lack of significant
 
electroosmosis, the loading and returning of a sterile system, the capture
 
of the resulting separation, the preservation of the viable cells in orbit
 
and their subsequent return, all represent a "first" for space
 
electrophoresis. In addition, the newer methods of separation represented
 
by the isotachophoresis runs proved the feasibility of conducting large
 
particle processing by this method. The red blood cells in both columns
 
demonstrated sharp boundaries indicative of successful isotacho runs."
 
At this time, experimentation of bioprocessing is continuing with the Space
 
Processing Applications Rocket (SPAR) project. These experiments will
 
continue until the Spacelab becomes operational.
 
6
 
1.3 SPACE SHUTTLE SOON TO BE A REALITY
 
Space Shuttle'operations are scheduled to begin inthe early 1980s. The
 
operational goal of the Space Shuttle Program is to provide low cost trans­
portation to and from earth orbit, utilizing reusable orbiters with cargo
 
bays 15 x 60 feet in size. NASA is currently determining the traffic model.
 
1.3.1 Spacelab
 
Some of the missions will be equipped with a Spacelab which is a laboratory
 
designed for space operations, composed of modules and pallets in the orbiter
 
suitable for accommodating instrumentation for conducting research and
 
applications activities on Shuttle Sortie missions. On a given mission, the
 
Spacelab configuration can be comprised of a module only, a pallet only, or
 
a combination of a module and a pallet, leaving the arrangement flexible for
 
specific experiment or processifig applications. The Spacelab program is
 
under the direction of the European Space Agency in cooperation with NASA.
 
Flights will last from 3 to 30 days and scientists will have the opportunity
 
to fly with their experiments. The Space Shuttle/Spacelab will provide the
 
attractive features of the space environment with the capability for frequent,
 
repetitive reuse of the processing equipment.
 
1.3.2 Capabilities 'and Opportunities for Bioprocessing on Spacelab
 
The 1974 NASA Preliminary Sortie Payload Descriptions describes fifteen space
 
processing applications payloads. I0 Of these, bioprocessing isdesignated as
 
part or all of six payloads which will comprise some 40, or more, missions over
 
a decade. The Space Bioprocessing Program isdesigned to explore the
 
possibility of accomplishing bioprocessing and manufacturing that is too
 
difficult, costly, or impossible to accomplish on earth.
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Details of apparatus to be available on the Spacelab are not yet resolved as
 
the entire program is still in the development stage. Work is underway to
 
develop equipment necessary to perform electrophoresis in space, while
 
research and development in space processing is continuing with ground based
 
investigations and the suborbital rocket experiments.
 
Despite the lack of exact specifications of apparatus for the Spacelab, it is
 
known that weightlessness provides better control of certain parameters in
 
biological and biochemical manufacturing, e.g.,11
 
Absence of convection and sedimentation
 
More stable emulsions from immiscible fluids
 
Separation of materials difficult to isolate in one-g
 
Processing in liquid float zones without the use of a container
 
Mass transfer in liquids, wholly controlled by diffision.
 
Space processing of biological materials is an emerging technology. Many
 
possible applications have been defined. Included are the following:
12
 
Separation: Electrophoresis, dialysis and other separation techniques may
 
lead to ultra-purification of fragile biological substances, e.g.,
 
Specific cell types and mutants
 
High density lipoproteins
 
High purity erythroprietin
 
Factor VIII (antihemophilic factor)
 
Virus sub-unit vaccines
 
Sub-types of immunoglobulin G
 
High purity biologicals uncontaminated by antigenic residues.
 
Biosynthesis: Zero-g fermentation and tissue culture may lead to new syntheses
 
of these biologicals which are impractical to produce on-Earth, e.g.,
 
8 
Medically important biologicals produced from hydrocarbons and other
 
immiscible substrates
 
New vaccines and antibiotics
 
New hormones and enzymes from specific cell lines
 
Production of reactive intermediates which are required in the
 
manufacture of certain biologicals on Earth
 
Manufacture of certain primary metabolites (amino acids, nucleotides,
 
etc.), made possible by altered microbial feedback controls, due to
 
zero-g.
 
There are already many uses for pure cell lines in the manufacture of a variety
 
of vaccines and other biologicals through tissue culture. We are presently at
 
the threshold of a large potential for clinical use of pure cell populations
 
to correct genetic or acquired deficiencies.
 
One can also envisage far reaching applications of better protein fractionation
 
in space. Human plasma proteins and a variety of enzymes, protein hormones,
 
etc., are presently fractionated on a large industrial scale for medical and
 
research usage. The methods presently used all lack the sensitivity and
 
resolution of electrophoresis and often give products of insufficient purity
 
at low yields. Thus, it is hoped that the space bioprocessing payloads will
 
be directly applicable to ground-based industrial/biological processes.
 
NASA and ESA are responsible for developing the space technology needed for
 
practical space processing applications. There are numerous opportunities for
 
bioprocessing in space on the Spacelab. The details will be developed through
 
the interaction of private industry, the scientific community, NASA and ESA.
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1.4 	 STUDY PURPOSE
 
1.4.1 	 Begin Analysis of Benefits that may Accrue from Bioprocessing
 
in Space
 
The purpose of this study is to perform a preliminary economic benefits
 
assessment of space processing of certain biological materials. The
 
objective of this assessment is to provide improved understanding of the
 
economic potential of space processing for those selected biological
 
materials. Additionally, areas which are significant for further analysis
 
and decision making will be indicated. Inpursuing this task, two case
 
studies are made of the applications of space processed biological ma­
terials. The two materials investigated here are'human lymphocytes and
 
urokinase. The users of the first material, if it can be successfully
 
separated so as to yield medical usefulness, would be patients, or po­
tential patients, of kidney transplants. The other material, urokinase,
 
would be utilized by persons suffering from-diseases involving blood clots.
 
1.4.2 	 Benefits Only
 
Itshould be made clear at this point that this study does not attempt to
 
determine costs. Thus, this study isnot a cost-benefit analysis. However,
 
the analysis presented here could be used in a cost-benefit analysis once the
 
costs are generated. The responsibility for generating cost data lies with
 
NASA at this time.
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2. CASE STUDY DISEASES AND TREATMENT SYSTEMS
 
2.1 END STAGE RENAL DISEASE
 
The healthy human body contains two kidneys which maintain the delicate
 
chemical balance required for normal body functioning. Each day the
 
kidneys filter some 200 quarts ofblood and about two quarts of wastes
 
and harmful substances are discharged as urine. Because each kidney can
 
,process volumes many times greater than it normally does, one kidney can
 
suffice if the other is removed or ceases to function. If the kidneys do
 
not remove wastes from the blood, uremia, or urea in the blood develops.
 
Advanced uremia will ultimately lead to death. The severity of uremia
 
parallels the extent of kidney failure. 
 When the kidneys are chronically
 
at a functional level of 5 percent or less the condition is known as End
 
Stage Renal Disease (ESRD). This condition is irreversible.
 
2.1.1 Epidemiology of ESRD
 
In any one year, approximately 50,000 people face kidney failure. 13,14,15
 
Of these, about 10,000 are medically suitable candidates for dialysis or
 
transplantation, 16 the two current means of treatment. Although the 50,000
 
figure is difficult to substantiate with vital statistics, the figure is
 
commonly mentioned in the literature. The number of persons who are
 
medically suitable for dialysis or transplant are estimated to be about
 
10,000 annually and is becoming easier to pinpoint because of improved
 
government statistics on the matter.
 
The improvement in government statistics on 
ESRD care has come about because
 
of the commitment of the federal government through enactment of Section
 
2991 of Public Law 92-603, to cover costs of treatment of ESRD. This is
 
the first major chronic disease for which the government has assumed
 
financial responsibility. This coverage is not entirely universal as it is
 
available only to those who qualify for Social Security coverage, thus some
 
5 to 10 percent of the ESRD population may not be eligible for coverage.
 
Testimony at House hearings on the ESRD Medicare coverage have revealed that.
 
costs are running much higer than anticipated. Currently government costs are
 
running over $300 million per year and are expected to reach the $1 billion mark
 
within ten years. 17 Data collection on ESRD treatment coverage is an evolving
 
II
 
technique on the part of the government and should be greatly improved
 
in about a year's time when the combined Social Security Administration
 
and Bureau of Quality Assurance reporting and computer analysis system is
 
18

operational. 

ESRD tends to afflict people of all socio-economic levels. 19 The sex and
 
age distribution is less evenly distributed. A slightly higher incidence
 
of ESRD is found among males than females. Fifty-four percent of patients
 
on hemodialysis were between the ages of 40 and 65 when they began dialysis.
20
 
However, less than 5 percent of the patients were under age 20 and less than
 
9 percent were over age 65. 21 Seventy-five percent of the males and 65 per­
22

.cent of the women were of working age. This mean age was 48 for men and
 
47 for women.
 
2.1.2 Present Treatment of ESRD
 
2.1.2.1 Dialysis
 
When the human kidneys fail to function a machine can be utilized to filter
 
wastes and water from the blood. The process is called hemodialysis, or
 
peritoneal dialysis if the fluid in the intestinal cavity is filtered rather
 
than the blood. If dialysis is not utilized, the ESRD patient will die
 
within about a month's time. On April 1, 1976, the last available count,
 
the total number of patients on dialysis was 18,323.23 This information is
 
from the National Dialysis Registry which collected the data from 546 centers
 
but as of May is no longer gathering data in lieu of the new joint Social
 
Security - B.Q.A. system, which is not yet operational. Although there may
 
be more patients than are reported by the Registry, this is the most accurate
 
figure available.
 
Dialysis can take place in one of three settings:
 
1) a hospital,
 
2) a treatment center, or
 
3) the home.
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The hospital isconvenient for the physician because ifthe patient needs
 
medical attention the personnel isavailable. Additionally some patients
 
present complex medical problems which predispose them from home dialysis.
 
Hospital dialysis accounted for 52 percent of all dialysis patients in the
 
most recent Registry.24 Treatment center dialysis accounted for one­
quarter of dialysis patients and offers some of the benefits of a hospital
 
but still involves transportation of the patient to the center. Home
 
dialysis isclaimed to be cheaper than facility or hospital dialysis because
 
of the reduced cost of medical personnel other than the doctor. The
 
patient or spouse performs many of the tasks often performed by nurses or
 
technicians.
 
2.1.2.2 Transplants
 
The other medical treatment for ESRD isto surgically transplant another
 
functioning kidney into the patient's intestinal cavity. Table 2.1.1 gives
 
the total number of transplants performed in the United States at slightly
 
less than 15,000, and averaging around 2,000 per year. The sources of
 
healthy kidneys for such transplants are either living persons who are
 
willing to give up one of their functioning kidneys (usually a relative
 
of the recipient), or those who have healthy kidneys and are suddenly
 
killed or die (generally automobile accident victims).
 
Table 2.2.1 indicates the breakdown of transplants by donor source, the
 
largest percentage being cadaveric donors. Table 2.1.2 gives the survival
 
rate of transplanted kidneys. From experience in the United States, generally
 
itcan be observed that transplants from relatives function longer than from
 
cadavers, and the record for five-year transplant survival has improved in
 
recent years. Taking the five-year figures for the year 1970 from Table
 
2.1.2, there was an overall functioning kidney survival rate of 47 percent.
 
Table 2.1.1 Kidney Transplant Statistics for the United States
 
TOTAL KIDNEY TRANSPLANTS BY YEAR
 
1953-
1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 
TOTAL 
TO DATE 
United States 1,146 462 701 870 1,137 1,674 2,221 2,402 2,181 1,742 14,536 
TRANSPLANTS RECORDED TO DECEMBER 1, 1975 
United States 
Donor Source 
Parent 
Sibling 
Cadaver & Unrelated Living 
Monozygotic Twin 
Other Related Living 
Total Recorded 
Number of 
Transplants 
2,367 
2,896 
8,823 
69 
381 
14,536 
% of Total 
16.28 
19.92 
60.70 
.48 
2.62 
100.00 
SOURCE: American College of Surgeons, N.I.H. 
Table 2.1.2 Functional Survival of First Kidney Transplant
 
I , 
Donor Source 
Sibling 
Parent 
Cadaver 
Table 3.-Percent Functional Survival (S'-SE)of First Transplant 
Year of Transplant Sample Size I yr 2 yr 3 yr 
1951-1966 246 63 8±3 1 57 2-'3 2 53 0±3 2 
1967 148 77.0±35 70.2 L3 8 65 4±3.9 
1968 203 80 3±2,8 74 3±3.1 71 3±3.2 
1969 217 76 5±2 9 71 8-'3 1 69 4"3 1 
1970 266 81 ±.124 78.22 6 72 8±2.9 
1971 406 73 7±2 2 69 6±2.3 67 7±2.5 
1972 447 709± 1.9 73.7±2 5 . ... 
1951-1966 412 51002 5 49.7±2 5 44 9:2.5 
1967 152 71.7±3 7 61,8±3 9 55 9±40 
1969 208 73 1±31 67 8±3 2 60 4±3.4 
1969 234 69.2±3,0 62.2±-3 2 56 3'L3 3 
1970 261 73 8±2 7 08.3±J2.9 62 3' 3 1 
1971 326 73 7±2 4 66.8±2 7 62 33.1 
1972 359 71 7±2.4 31. 
1951-1966 685 35 6±1.8 27 9±1 7 22 4:kI,6 
1967 395 45 6±2 5 38.9:!2 5 34 2-2.4 
1968 649 47 6±2 0 40 4±1.9 35 2-1.9 
1969 847 54 2--1 7 47 2±1 7 42 1: 1,7 
1970 1,147 55.3±1 5 47.2±1 5 42 0 1 5 
1971 1,559 53.1-1 3 45.7±2l 3 41 8ar1.4 
1972 1,707 50 6±1 2 42 6-.1 4 
4 yr 
49 2"-l3,2 
58 4± 4 1 
65 6±3 4 
64 33 3 
69 6±3 3 
5 yr 
46 2±3 2 
55,2±4.2 
61.8±3.5 
60 8±3 7 
42,3±2 5 
52 5±4,1 
53.6±3 5 
49,2-:3 4 
57.3±3 6 
6 
39 9:!2 5 
50.L±4.1 
St 0±3 6 
42 0±3 8 
. 
19.-4±1 5 
29 2-L2 3 
32.8-I 9 
37 9±1.7 
40 6±1 6 
16,0±1 4 
267±2 3 
30.2-"1 9 
35 2±1.9 
.. 
SOURCE: American College of Surgeons/N.I.H.
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The other significant factor in kidney transplantation is the patient
 
survival rate. Table 2.1.3 lists kidney transplant patient survival rates
 
for up to five years. The same generalizations of kidney function survival
 
apply to patient survival; however, patient survival is greater than kidney
 
function survival with 56 percent of the 1969 graft population surviving
 
5 years. Of all transplant patients for which there is follow-up data,
 
67 percent are still alive and of those 70 percent still have functioning
 
kidney transplants. 25 A transplant patient often outlives his transplant.
 
A patient with a nonfunctioning transplant either receives another
 
transplant or returns to dialysis. There is often a considerable wait to
 
receive a transplant due to availability and tissue matching. A cadaveric
 
kidney is only viable for about 3 days before it must be used or discarded.
 
Kidney transplants are not yet a solution for every patient because of the
 
high failure rate. There is no single cause of graft failure, but over 60
 
percent of the transplants reported as failing were lost due to the body's
 
rejection.26 Approximately 10 percent of kidney grafts are lost due to
 
technical difficulties. 27
 
Presently patients with kidney transplants are given some type of antilymphocyte
 
globulin which essentially suppresses all lymphocyte activity.28  One side
 
effect of such an action is a marked increase in the incidence of cancer in
 
29
 
transplant patients.

The immunologic system of the human body is not well understood; medical
 
research is continually making new discoveries in this field. It is known
 
that immunity is caused by the formation of substances called antibodies.
 
Immunities have been found to be specific, that is, they protect the person
 
only against the disease-causing agent used to develop the immunity. The
 
thrust of present research is to find the specific immunity factor or factors
 
attacking a transplanted organ, such as a kidney.
 
Table 2.1.3 Kidney Transplant Patient Survival
 
Table 4.-Percent Patient Survival (.':SE) of First Transplant 
Donior Source Year of Transplant Sample Size I yr 2 yr 3 yr 4 yr 5 yr 
Sibllng 	 1951-1966 246 68 1 i3 0 61 9±t3 2 58.3±3 2 56 0 --3.3 54 0:3 3 
1967 148 83.6-3 1 76 9±3 6 72 4:-3.8 66 1 "4 I 63,314.2 
1968 203 88 l±2 3 82 6±2 8 79 8±29 76,3".3 1 73 3 - 3 3 
1969 217 82.6±2 6 78 5±2 9 774 L2 9 72 4 t 3.2 71 "-35 
1970 266 860-±-2.2 84 2±2 3 81 O±2 6 81 0±52 6 
1971 406 85,2±I1 9 81 8±2 1 80 3±23 
1972 447 90,9±1 4 86 8±2 I ... 
Parent 	 1951-1966 412 61.012 5 56 5-:2,5 53 0±2 6 51 I L2 6 SO5±"2.6 
1967 152 75 4"L3 6 69 0±"3 8 63.8.' 40 62 2:L4 I 60 3 t4.2 
1968 208 80 0'!'2 8 76 2±30 71.7:-32 67.23 5 656 -36 
1969 234 78.7"'.2 8 73 7'3.0 69 8."3 2 64 6' 3 5 61 8:1'3.8 
1970 261 84 2:2 4 80 0±2 6 70.,9L2 7 77 6"-!2 9 
1971 326 86 1 L2 0 82 3-L2.3 80,4±2 6 
1972 359 866 119 81 8±2,6 , ,. 
Cadaver 	 1951-1966 665 42 I-2 3441 9 28.-t 9 25.7 t1 8 23 I--I 8 
1967 395 56.3 2,7 49 5±2,7 45.1 -2 8 40 0- 2 0 39 2 L2 8 
1968 649 5862 1 5l62l L2 4, 2.2 4 7"22 4313:±2 2 
1969 847 65,5: 1 7 59 3;L 1 8 55 9 51719 5016 '!2 
1970 1,147 69 2 I 3 11.1 58 4"' 17 57,(;-! 1.7 . , 
1971 1.550 (92'13 6341 61 511 5 
1972 1,707 71.0' 1 2 65 6 1 6 
SOURCE: American College of Surgeons/N.I.H.
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2.1.3 	 Potential Alternative Treatment of Kidney'Transplant Rejection
 
By Regulating Lymphocytes
 
It is not clearly understood yet what effect the antilymphocyte gl'obulins
 
have on human immune mechanisms, especially in terms of specific immulogic
 
responses such as graft (transplant) rejection. Lymphocytes play a pivotal
 
role in many immune functions. Tissue typing of both donor and recipient
 
is often performed to try and match the HL-A antigens. To date, two major
 
types of human lymphocytes have been identified, T and B lymphocytes.
 
However, it is hypothesized that there are many subgroups within these
 
major types. It is hoped that the sorting of lymphocytes into subgroups
 
will isolate the lymphocyte or lymphocytes which specifical-ly affect
 
transplant immunologic responses. If those functionally specific
 
lymphocytes can be segregated, it is theorized that an enhancing antibody
 
could be developed to promote kidney transplant acceptance.
 
Lymphocytes are one type of white blood cells, or leukocytes. There are
 
five types of leukocytes: neutrophiles, baseophiles, eosinophiles,
 
lymphocytes, and monocytes. Lymphocytes, monocytes, and neutrophiles
 
react phagocytically, that is, they engulf foreign cells when encountered.
 
2.1.4 	 Limits of Earth Processing for Lymphocyte Separation
 
The present constraint on sorting, or separating lumphocytes into the many
 
subgroups which are theorized to exist, is the large cell size. Present
 
ground-based separation technology, such as electrophoresis, i-s limited in
 
the size of the material which can be separated due to convective turbulence
 
and sedimentation, both gravity induced factors. Thus, further research on
 
human immunology is constrained by technical difficulties in cell separation
 
procedures due to natural environmental characteristics.. It is necessary to
 
either eliminate gravity or develop procedures to separate cells in another
 
manner. It is theorized, and indeed early space experimentation is supporting
 
18 
the theory, that a convection free weightless environment may provide the
 
proper setting for utilizing electrophoresis to separate biological
 
materials by the size of cells. It is also theorized that isotachophoresis
 
performed in space would yield very distinct separation resolutions.
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2.2 THROMBOEMBOLIC DISEASES
 
2.2.1 Epidemiology of Thromboembolic Diseases
 
Clot diseases can be divided into two categories, stationary and mobile.
 
Thrombus isthe medical term for a stationary clot. A mobile clot, one
 
that is in motion or has migrated from a vein into an organ, such as the
 
lungs, is called an embolus. Thus, generally diseases related to clots
 
are called thromboembolic diseases.
 
A clot or thrombus, starts out in a stationary situation and can become
 
mobile,or an embolus. A clot in the leg, for example, known as deep vein
 
thrombosis, if uncorrected, can lead to two major and serious diseases:
 
pulmonary embolism, a mobile clot which has lodged in the lungs and can
 
cause death within minutes or an hour of its occurrence; and chronic venous
 
insufficiency.
 
Thromboembolic diseases can affect the eyes (.retinal vein thrombosis),
 
cause heart attacks (myocardial infarction) and cause problems in other
 
parts of the body.
 
Urokinase, a drug which appears to be able to dissolve blood clots, has been
 
tested experimentally in the United States but only to a limited degree.
 
The one disease for which data exists on urokinase efficiency is pulmonary
 
embolism. Because of the limited data availability, pulmonary embolism
 
statistics will be used in this report to generically represent thromboem­
bolic diseases. Thus total benefits may be somewhat understated because
 
urokinase may be of some benefit to diseases other than pulmonary embolism,
 
as has been found to be true incountries where urokinase i's commercially
 
available.30 However, due to the complete uncertainty of the medical
 
efficacy of urokinase on thromboembolic diseases other than pulmonary
 
embolism, only pulmonary embolism will be referenced in this study.
 
About 300,000 persons are hospitalized annually and more than 50,000 die
 
with pulmonary embolism.31 This number of deaths annually due to pulmonary
 
embolism is difficult to substantiate with vital statistics. Dr. Isadore
 
Rossman researched the question of accuracy of diagnosis of death as reported
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on death certificates. When autopsy reports were compared with death
 
certificates, an underreporting situation was found.32 Rossman indicated
 
that only one-half of one percent of death certificates listed pulmonary
 
embolism as the cause of death while the actual percentage ismore like
 
three percent of all deaths.33 Using Rossman's estimate, the total number
 
of persons dying from pulmonary embolism each year would be over 50,000.
 
Thromboembolic diseases mostly afflict the elderly. There is a high
 
incidence of clot formation in patients who have undergone surgery and
 
are immobilized for a period of time following the surgery. This is one
 
reason patients are asked to move around after surgery sooner than was
 
the practice in the past.
 
2.2.2 Present Treatment of Thromboembolic Diseases
 
2.2.2.1 Heparin
 
Presently the treatment of thromboembolic diseases consists of either an
 
anticoagulent regime or surgery. Heparin is the generic name of a
 
pharmaceutical product that acts as an anticoagulent, that is,it prevents
 
blood from clotting. Heparin isoften given as a therapeutic agent in
 
routine dosages for extended periods of time. Heparin ismade from an
 
enzyme which is found in the human body.
 
2.2.2.2 Surgery
 
Heparin may prevent further clotting action while the body naturally breaks
 
down the thrombus, or clot. Heparin alone cannot dissolve the clot, it
 
can only prevent the formation of new ones. When a clot is indanger of
 
migration, or has migrated and lodged in a new location, such as the lungs,
 
surgery may be necessary to physically remove the embolus, or migrated
 
clot. Thus surgery, commonly a pulmonary embolectomy, isoften performed,
 
as a remedy. It is major surgery and expensive. Once an embolus has reached
 
the lungs, however, the body is in a life critical situation. Twenty to
 
fifty percent of the deaths resulting from pulmonary embolism occur within
 
a few minutes to an hour.3
4
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2.2.3 Potential Alternative Treatment Utilizing Urokinase
 
Urokinase is an enzyme found naturally in the human body which acts as a
 
plasminogen activator. Urokinase produced in the kidneys can be found in
 
trace amounts in the urine. It has been established by the biomedical
 
research community that urokinase is capable of activation of the
 
fibronolytic system. That is,urokinase added to the bloodstream appears
 
able to lyse, or dissolve, blood clots.
 
When a clot, or thrombus, forms in the body, a precursor in the blood
 
called fibronogen has changed into fibrin, the material which composes
 
the clot. Fibrin is deposited by the body in an early phase of tissue
 
repair. When a thrombus is young, it is composed of soluble fibrin,
 
which is denoted fibrin(se). In a matter of about a week after the
 
thrombus has initially formed a substance called Factor XIIIa combines
 
with fibrin(se) to produce an insoluble form of fibrin, denoted fibrininsol).
 
To produce the lysing action, urokinase is given to the patient. Urokinase
 
activates another precursor occurring naturally in the blood called
 
plasminogen. The combination of urokinase and plasminogen produce plasmin
 
which is capable of digesting proteins such as fibrin. Thus, plasminogen,
 
urokinase and fibrin are components of the fibrinolytic system.
 
At present, urokinase is not commercially available in the United States.
 
Two drug companies have applied to the FDA for approval to market the
 
substance.35  In 1967 the National Heart and Lung Institute organized a
 
controlled clinical trial to evaluate the thrombolytic capability of
 
urokinase. Pulmonary embolism was chosen as the disease model in which
 
to evaluate a thrombolytic agent because dianostic techniques (pulmonary
 
angiography and perfusion lung scanning) permitted quantitative assessment
 
of both preinfusion severity and resolution of emboli. Phase 1 of the trial
 
was called the Urokinase Pulmonary Embolism Trial (UPET) while Phase 2
 
was called the Urokinase - Streptokinase Pulmonary Embolism Trial (USPET).
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Phase 1 established that urokinase increased the resolution rate of pulmonary
 
thromboemboli, especially massive emboli, as judged by arteriography,
36
 
hemodynamics, and lung scanning. Figure 2.2.1 gives the relative
 
improvement of urokinase over heparin from the UPET while Figure 2.2.2
 
indicates the relative improvement over time of heparin and urokinase
 
patients in the test. There was no significant difference in mortality
 
between the two groups. This may have been due to the small sample but
 
the carefulness which characterized the selection of patients may have
 
weeded out the high risk patients from the sample.
 
2.2.4 	 Limits of Earth Processing for Cell Separation to Obtain Urokinase
 
Producing Cells from Kidney Cells
 
Urokinase can be obtained from two basic methods: extraction from urine
 
or extraction from kidney cells. The first method, extraction from urine,
 
is the technique utilized by foreign pharmaceutical firms which offer
 
urokinase commercially. There are drawbacks to this technique.
 
Some 1500 liters of urine are needed to obtain one dose of urokinase.
 
In addition to the logi-stics of obtaining large quantities of urine,
 
there are purity problems because fever producing precursors often cannot
 
be removed from the urine.
 
The other 	technique is to separate the urokinase producing cells from other
 
kidney cells either before or after all the cells have been propagated. A
 
procedure has been developed by Abbott Labs making use of tissue culture
 
techniques using the Mass Tissue Culture Propagator.37 In this procedure,
 
all kidney cells are propagated, not just the ones which produce urokinase.
 
A 95 percent reduction in the number of cells to be cultured would greatly
 
reduce production costs and possibly lead to greater purity.38 However, at
 
present, techniques do not exist which allow successful kidney cell
 
separation on earth. It has been theorized that electrophoretic separation
 
of kidney cells in a gravity-free environment might prove to be the answer.
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Thus if kidney cells could be transported to space, separated as to cell
 
function, and returned to earth in a viable condition, only the urokinase­
producing cells would have to be propagated in earth-based facilities.
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3. POTENTIAL IMPACT OF SPACE PROCESSING ON CASE STUDY DISEASES
 
3.1 MODELLING OF PRESENT AND FUTURE TREATMENT SYSTEM IMPACTS ON SURVIVAL
 
3.1.1 Model Concepts
 
Ina quantitative approach to human disease process analysis, it is common
 
to speak of "states" that a patient may occupy. Clearly, two such states
 
could be "healthy" and "sick". A more detailed breakdown might include the
 
states "healthy", "slightly affected", "sick", and "seriously affected".
 
Of course, the choices of states are unlimited.
 
In modelling an individual's movement through the various states, we are
 
in effect, defining the process that the disease takes. Inmathematical
 
terminology, we are defining the "transitions" allowed and the "likelihood"
 
of each transition. For example, healthy people can go from the "healthy"
 
state to the "sick" state, and a sick person can go from the "sick" state
 
to the "healthy" state. Allowing "death" to be one state, we note that it
 
is possible for persons in the "sick" state to go to the "death" state, but
 
not vice versa. It is most useful to make a diagram of the possible states
 
and the transitions allowed. Figure 3.1.1 illustrates such a diagram. A
 
more complicated example illustrates a more'realistic problem, as.portrayed
 
inFigure 3.1.2. This example illustrates a particular structure to the
 
problem under analysis. Sick people can become healthy without any treatment
 
and without a doctor's attention. Sick people can administer Treatment No. 1
 
to themselves, but not Treatment No. 2. If a doctor is seen, then both
 
treatments are viable. Death can be reached from any state directly, except
 
from "Under Doctor's Care". Here it isassumed that treatment is immediately
 
given, after which the patient either transitions to the "healthy" state or
 
to the "death" state. How one defines the problem structure dictates the
 
definition of states and the allowable transitions among them.
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FIGURE 3.1.1 SIMPLE EXAMPLE OF ALLOWABLE TRANSITIONS AMONG DISCRETE STATES
 
____ ___ ______ _______ ___ ___ ____ ___ ___DEATH 
HEALTHY
 
SIC 
UNDER 
DOCTOR'S 
CARE 
TREATMENT 
NO.1I 
TREATMENT 
NO. 2 0 
FIGURE 3.1.2 EXAMPLE OF ALLOWABLE TRANSITIONS AMONG DISCRETE STATES 
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The next step in defining a mathematical model such as this is to indicate
 
the likelihood of each possible transition. That is, if a patient is in
 
State i, what is the probability he -ill transition to State j? These
 
probabilities can be written alongside the transition arrows as shown in
 
Figure 3.1.3.
 
In this example, 90% of healthy people remain healthy; 9% contract the
 
disease under question; 1% die of other causes. Once sick, a patient
 
has a 10% change of becoming healthy without doing anything. He has a
 
10% chance of dying immediately from the disease; there is a 60% chance
 
he will seek a doctor's care; and there is a 20% chance he will administer
 
Treatment No. 1 to himself. If he goes under a doctor's care, 25% of
 
the time, the doctor will administer Treatment No. 1 and 75% of the time,
 
the second treatment. Of those receiving the first treatment, there is
 
a 50 - 50 chance of surviving. Of those receiving the second treatment,
 
there is a 95% chance of survival.
 
Having stated the transition probabilities, we identify now the times at
 
which transitions are allowed. In a "discrete" process, the transitions
 
occur at predetermined times, such as once every day, or once every hour.
 
If the transitions can occur at any point in time, and if this time depends
 
only on the current state and the state to be transitioned to, the process
 
is called "continuous". For example, the time in State "Treatment No. 1"
 
may be one day, while the time in State "Treatment No. 2" may be one week.
 
The final issue of concern in such a model (which our examples already
 
implicitly assumes given) is whether or not the process is "Markovian".
 
If the likelihood of transitioning from State i to State j depends only
 
on i and j, and in no way depends on what states have been occupied prior
 
to arriving in State i, we call the process "Markovian". Otherwise, it
 
is called "Non-Markovian"K In our example, having stated the transition
 
probabilities in the manner we have, we have already assumed the process
 
to be Markovian. For example, we have assumed that a patient has a 50 - 50
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chance of survival after Treatment No. 1, regardless of whether it is self­
administered or given by a doctor. If this assumption isnot valid for
 
a given problem, what isrequired is a more detailed breakdown of the
 
states in order to maintain the Markovian property. Figure 3.1.4 illustrates
 
such a change to the model.
 
Through a redefinition of the states, we have maintained the Markovian
 
property and have distinguished the likelihood of success with self­
administration of the first treatment from that administered by a doctor.
 
The benefit of maintaining the Markovian property is that most mathematical
 
results are simplified and the characteristics of the process easily
 
understood and described. With the availability of modern high-speed
 
computers, however, the necessity of making compromising assumptions in
 
order to maintain the Markovian property has been lessened. Today, more
 
realistic modelling can be utilized through simulation techniques wherein
 
each transition israndomly simulated. The history of the transitions can
 
be kept and utilized to the extent necessary to determine subsequent transitions.
 
Additionally, probability distributions and other characteristics can be
 
both used and determined through the simulation process.
 
3.1.2 Model
 
In the study of the effect of biological space processing, we chose the area
 
of lymphocyte cell separation, and urokinase cell separation, and then on
 
specified disease treatments, we specifically address the diseases known as
 
End Stage Renal Disease (ESRD) and pulmonary embolism. The application of
 
the model to the two disease treatments will be covered separately.
 
The treatments for ESRD known today are dialysis and transplant and for
 
pulmonary embolism, surgery and the administration of the drug heparin. As
 
stated earlier inthis report, it is believed that through lymphocyte separation
 
in space, a better understanding of the body's immunological system will come
 
about, resulting in better tissue matching and hence, a greater success rate
 
in transplant operations.
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Initially eight states were defined as shown in Figure 3.1.5. In this
 
figure the possible transitions are shown. Note that all five states
 
encircled are possibly reached after contraction of ESRD. These five
 
states were singled out for the model thereby ignoring healthy people
 
and those who had kidney disease, but not ESRD. We defined a discrete
 
Markov Process for these five states, dictating that each year, a
 
transition would occur (possibly resulting in no movement at all, but
 
transitioning back to the same state).
 
What we desired to collect were a host of statistics that would allow us
 
to compare the potential benefits of space processing of lymphocyte
 
separation. We defined three cases with which to exercise the model:
 
(1)current status; (2)partial improvement due to space processing;
 
and (3)optimistic improvement due to space processing.
 
Among the statistics we collected for each case were:
 
(1) How long did the patient live after contracting ESRD?
 
(2) How many years after contracting ESRD did the patient
 
enter each state?
 
(3)- How many years did the patient "reside" ineach state?
 
(4) Cost to Public Sector
 
(5) Cost to Private Sector
 
Through consultation with experts inthe area of kidney disease and kidney
 
transplants, and by absorbing as much data as were available on the
 
problem, we determined transition probabilities for each of the three cases.
 
A convenient method used to represent the transition probabilities is
 
through a matrix. The matrix isarranged with the present states listed
 
vertically on the left of the matrix and the states which can be entered
 
horizontally across the top. Thus, by following the column across the
 
matrix the probabilities can be seen for entering any other state. There
 
are certain transitions that are not possible and those transition boxes
 
are darkened on the matrix inthe figures (or given a value of zero).
 
Figures 3.1.6, 3.1.7 and 3.1.8 show the transition matrix for each of the
 
three cases of kidney disease treatment.
 
GENERAL DEATH 
POPULATION/ 
DISEASE /DIALYSISDIALYSIS \ 
\ PLANT POS 
\ / 
MODELLING OF KIDNEY DISEASE 7 
Figure 3.1.5 
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FIGURE 3.1.6 PROBABILITY MATRIX ESRD BASELINE CASE
 
SOURCE:
 
Probability transitions determined from analyzing the statistics on the
 
number of persons contracting ESRD annually, the number receiving dialysis,
 
the number receiving transplants and the estimates of the percent dying the
 
first year of ESRD. Sources include:
 
a 	 House of Representatives, Hearings Before the House Subcommittee
 
on Oversight on Medicare's End-Stage Renal Disease Program, G.P.O.,
 
June 24 - July 30, 1975.
 
a 	 National Dialysis Registry, National Institute of Arthritis and
 
Metabolic Diseases, N.I.H., Bethesda,'Maryland, October 1, 1975.
 
* 	 Advisory Committee of the Renal Transplant Registry, The Twelfth
 
Report of the Human Renal Transplant Registry, J.A..A., August
 
18, 1975.
 
* 	 Rogosin Kidney Center, Annual Report, The New York Hospital -

Cornell Medical Center, New York, New York 1975.
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FIGURE 3.1.7 PROBABILITY MATRIX OF ESRD PARTIAL IMPROVEMENT CASE
 
SOURCE:
 
Probability transition determined mainly by utilizing the transplant success
 
rate being experienced at the Rogosin Kidney Center with a projection of
 
increased length of time before rejection of the transplant. See:
 
a 	 Rogosin Kidney Center, Annual Report, The New York Hospital -

Cornell Medical Center, New York, New York, 1975.
 
An assumption was made that if the survival rate for kidney transplants was
 
lower than for dialysis more patients and doctors would elect that treatment
 
made than present. Thus the probability of transition to the transplant
 
state was arbitrarily increased.
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FIGURE 3.1.8 PROBABILITY MATRIX OF ESRD OPTIMISTIC IMPROVEMENT
 
SOURCE:
 
Probability transitions determined after detailed discussions with Rogosin
 
Kidney Center medical staff and recognition of the maximum impact to be
 
the 60% of rejection cases sited as caused by the bodies immunological
 
response.
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Costs were obtained through research on government testimony, Social
 
Security Benefits reports, Office of Management and Budget reports and
 
an organization composed of dialysis patients. The initial cost
 
factors used are shown below and detailed breakdowns appear in the
 
appendix. These figures were inflated at a 6 percent compound interest
 
rate to reflect 1985 dollars (the first year benefits can be expected).
 
State Public Sector Costs Private Sector Costs 
First Year Dialysis $16,200 $15,250 
Continuing Dialysis 21,300 7,100 
Transplant 13,000 6,500 
Post-Transplant 0 500 
Death 0 2,500 
Inoperating the model for any of the three cases, an individual once
 
contracting ESRD was assumed to enter in the first state -- "First Year
 
Dialysis". At the first transition, he was randomly placed in the second,
 
third, or fifth states (since these are the only states possible). On each
 
subsequent transition, the patient moved from state to state according to
 
the probabilitlies given in the transition matrix, until the "death" state
 
was reached, at which point an iteration was complete. Statistics were
 
gathered for that patient as he moved from state to state. This process
 
was repeated many times (Monte Carlo Simulation) in order to have reasonable
 
confidence that the statistics generated were correct.
 
Results of the analysis are presented inSection 3.2.
 
The treatments of thromboembolic diseases, specifically pulmonary embolism
 
in this study, are heparin therapy and surgery. Additionally, the use of
 
the drug urokinase is speculated to become an effective treatment regime
 
once it receives FDA approval for use inthe United States and becomes
 
commercially available. It is anticipated that not only will urokinase lyse,
 
or dissolve, clots of the lungs, but also have the same effect on clots in
 
other parts of the body.
 
) T 	 IDEATHE(THROMOEMBO 

HEAI THAINSRERY 
THHERAPY 
Fiue3.1.9 	Transition States for
 
Thromboembolic Disease
 
and Treatment
 
40
 
Initally seven states were defined as shown in Figure 3.1.9. For the
 
simulation all states were utilized except the state representing the
 
general population. The state of thromboembolic diseases was not
 
eliminated due to the uncertainty of the transition probabilities for
 
the treatment modes. The uncertainty exists because urokinase is not yet
 
available and thus, no utilization rate exists.
 
What we desired to collect were a host of statistics that would allow a
 
comparison of the pre and post introduction of urokinase as a treatment
 
regime, and any impact the space processing may have on drug costs. Four
 
cases were defined: (1)current status; (2)initial improvement due to
 
the introduction of urokinase; (3)partial improvement due to increased
 
use of urokinase and a reduced mortality from its use; and, (4)optimistic
 
improvement with increased use of urokinase, decreased mortality and reduced
 
cost of urokinase.
 
Among the statistics we collected for each case were:
 
(1) How long did the patient live after contracting pulmonary embolism;
 
(2) How long did the patient "reside" in each state, particularly the
 
post-treatment state which represents recovery;
 
(3) Costs to the individual.
 
Transition probabilities were determined for each of the four cases through
 
consultation with experts familiar with urokinase efficacy and by analyzing
 
the literature on pulmonary embolism. The transition probability matrices
 
are given for each of the four cases in Figures 3.1.10, 3.1.11, 3.1.12,
 
and 3.1.13.
 
Cost estimates are based on actual experience in the case of a surgeon"s
 
fees, to an approximation based on costs in other countries inthe case of
 
urokinase. The degree of severity of an emboli determines costs and the
 
range isgreat. One patient may need surgery followed by intensive care
 
while another patient may be treated medically, only to have to undergo
 
surgery later. The average cost figures used are listed below:
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Figure 3.1.10 Probabil.ity Matrix of Thromboembolic Baseline Case
 
SOURCE:
 
Probability transitions determined by analyzing the statistics on pulmonary
 
embolism and urokinase experimentation. Sources include:
 
* 	Abstracts of the International Symposium on Urokinase, Rome
 
Italy, 1975.
 
* 	National Heart, Blood Vessel, Lung and Blood Program, Vol. 1
 
National Heart and Lung Institute Summary, National Heart and
 
Lung Institute-National Institutes of Health, DHEW, 1973, p. 10.
 
m 	American Heart Association, The Urokinase Pulmonary Embolism Trial,
 
A National Cooperative Study, Monograph #39, Supplement to
 
Circulation, April 1973, and "Urokinase-Streptokinase Embolism
 
Trial, Phase 2 Results" J.A.M.A. Sept. 16, 1974, Vol. 229, No. 12.
 
* Meeting with Grant Barlow, Abbott Labs, N. Chicago, Ill. Feb. 2, 1976
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T.E.
 
DISEASE HEPARIN SURGERY UROKINASE POST-LYSE DEATH
 
05 .30 .06 .50 -. .09 
T.E. DISEASE 	
__________ 
HEPARIN 	 .05 .03 .15 .68 .09
 
SURGERY 	 .02 .02 .06 .78 .12
 
UROKINASE ' '-: "I: "i}'
UR-KINA:" .03 .06 .82 .09
 
'° "  " ' 'vs.. . . o __ ___. . ...	 _, 	 _ ....... 

POST-LYSE 10 	 .02
f.88 

" 	 10DEATH - , ...." .. • -.	 1.0 
Figure 3.1.11 Probability Matrix of Thromboembolic Initial Improvement Case
 
SOURCE:
 
Probability transitions determined by analyzing the statistics on plumonary
 
embolism and urokinase experimentation. Sources include:
 
* 	Abstracts of the International Symposium on Urokinase, Rome
 
Italy, 1975.
 
a 	National Heart, Blood Vessel, Lung and Blood.Program, Vol. 1
 
National Heart and Lung Institute Summary, National Heart and
 
Lung Institute-National Institutes of Health, DHEW, 1973, p. 10.
 
o 	American Heart Association, The Urokinase Pulmonary Embolism Trial,
 
A National Cooperative Study, Monograph #39, Supplement to
 
Circulation, April 1973, and "Urokinase-Streptokinase Embolism
 
Trial, Phase 2 Results" J.A.M.A. Sept..16, 1974, Vol. 229, No. 12.
 
* 	Meeting with Grant Barlow, Abbott Labs, N. Chicago, Ill. Feb. 2, 1976.
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T.E. 
DISEASE HEPARIN SURGERY UROKINASE POST-LYSE DEATH 
T.E. DISEASE .05 .14 .06 .66 - 09 
:.', " X:' 
HEPARIN .05 .03 .20 .63 .09 
SURGERY""" " SURGERYi. .02 .02 .06 .78 .12 
UROKINASE . - . . .­
.03 .06 .86 .05
 
" "70 - .'" .02POST-LYSE • 0 "1-. .. , .88 .02
 
. [7W -•J"_" --DEATH:" ["9 . ..• .: ... ... " . -:- 1.0
 
Figure 3.1.12 Probability Matrix of Thromboembolic Partial Improvement Case
 
SOURCE:
 
Probability transitions were determined by lowering the mortality rate and
 
selecting a higher probability for transitioning to the urokinase treatment
 
state.
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T.E.
 
DISEASE HEPARIN SURGERY UROKINASE POST-LYSE DEATH
 
T.E. DISEASE 02 .14 .06 .76 .02 
HEPARIN j, .05 .03 .20 .63 .09 
SURGERY .02 .02 .06 .78 .12 
UROKINASE .03 .06 .89 .03 
POST-LYSE .10 88 .02
 
DEATH 1.0
 
Figure 3.1.13 Probablility Matrix of Thromboembolic Optimistic Improvement Case
 
SOURCE:
 
Probability transitions were determined by lowering the mortality rate and
 
selecting a higher probability for transitioning to the urokinase treatment
 
state.
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State Private Sector Costs 
Heparin Therapy $5580. 
Surgery 6440. 
Urokinase 
Normal 5970. 
Optimistic 4140. 
Death 2500. 
3.1.3 Other Medical Treatment Survival Rate Models
 
Although the model described in the previous subsection was derived by
 
analysis of the health care systems and without specific regard to similar
 
work previously performed for the sake of medical analysis, the precedence
 
for such an approach as this is firmly established in the literature.
 
Burton, Damon, and Dellinger39 have described procedures to estimate
 
transition probabilities using a combination of expert judgment and
 
empirical evidence. This work was specific to patient states for the
 
elderly. A patient was classified into one of thirty-two states (Pfeiffer
 
Patient States)40, reflecting the patients physical health, mental health,
 
social resources, economic resources, and mobility.
 
Cretin 41 , in a doctoral thesis inmodelling patient survival of myocardial 
infarction patients studied the short- and long-term effects of changes in 
pre-hospital and in-hospital care on survival after heart attacks. A ­
state transition model from heart attack to death was defined. 
Bush, Chen and Zaremba42 used Markov processes to evaluate treatment programs.
 
Weiss and Zelen43 used them to analyze the benefit of clinical trials.
 
An exhaustive survery was not undertaken, rather the above cases served to
 
substantiate the credibility of the model developed here. We have listed
 
the above only as a sample of the application of this modelling procedure
 
to the analysis of medical processes.
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3.2 Model Runs and Results
 
3.2.1 ESRD
 
One thousand iterations were run for the probability transition matrices
 
in Figures 3.1.6, 3.1.7 and 3.1.8 utilizing a Monte Carlo simulation.
 
The results of the simulation are given inTable 3.2.1.
 
As the transplant rejection rate and the death rate decrease, the life
 
expectancy of the average patient increases. The assumption was made
 
that as the kidney transplant rejection rate decreases, more patients will
 
elect that form of treatment and thus the probability of transitioning
 
to the transplant state was increased inthe optimistic case. Through a
 
reduced mortality for transplant patients, and an increase inthe number
 
of patients choosing that treatment, the expected patient life after
 
contracting ESRD was extended by almost 4 years inthe optimistic case.
 
Because the costs to both the government and the individual are both less
 
for the post-transplant state a reduced cost situation is encountered,
 
even with the extended four years of life.
 
3.2.2 Pulmonary Embolism Disease
 
The probability matrices in Ffgures 3.1.10 to 3.1.13 were run utilizing a
 
Monte Carlo simulation technique. The results of the runs are given in
 
Table 3.2.2.
 
Equal mortality rates were encountered in the urokinase efficacy experiments
 
conducted in the United States. When this was entered in the initial
 
improvement case, no increase in longevity was witnessed, but an increase
 
incosts was encountered due to the high expected price of urokinase.
 
In a parametric analysis the mortality was reduced in the partial and
 
optimistic improvement case. The result was a sharp increase in the mean
 
life expectancy of almost 13 years in the optimistic case.
 
Table 3.2.1 RESULTS OF ESRD TREATMENT SIMULATION
 
PARTIAL 

BASELINE IMPROVEMENT 

MEASURE STANDARD STANDARD 

MEAN DEVIATION MEAN DEVIATION 

"Age" *' AT DEATH 13.72 10.18 15.05 10.88 

COST TO PUBLIC SECTOR PER INDIVIDUAL
 
OVER INDIVIDUAL'S LIFE
 
UNDLSCOUNTED 430,262 (365,221) 324,313 (287,594) 

DISCOUNTED AT 10% 208,280 (132,714) 162,947 (113,368 

COST TO PRIVATE SECTOR PER INDIVIDUAL
 
UNDISCOUNTED 151,362 (126,065) 124,584 (107,105) 

DISCOUNTED 73,84a (45 563) 62,246 (41,116) 

* THROUGHOUT, "AGE" IS MEANT TO BE YEARS AFTER CONTRACTING ESRD 
OPTIMISTIC
 
IMPROVEMENT
 
MEAN 

17.11 

195,514 

108,231 

95,597 

41,890 

STANDARD
 
DEVIATION
 
11.44
 
(198,158)
 
( 93,147)
 
(76,894)
 
( 34,725)
 
.p-1 
TABLE 3.2.2 RESULTS OF THROMBOEMBOLIC TREATMENT SIMULATION
 
BASELINE INI. IMPROV. PAR. IMPROV. OPT. IMPROV.
 
CASE CASE CASE CASE
 
MEASURE STAN. STAN. STAN. STAN.
 
MEAN DEV. MEAN DEV. MEAN DEV. MEAN DEV.
 
"AGE"* AT DEATH 17.42 (10.98) 17.11 -(11.02) 21.64 (17.88) 30.79 (18.17) 
COST TO PRIVATE INDIVIDUAL 13,555 (8,876.) 14,356 (9,748.) 17,477 (14,151) 16,963 (10,461)
 
* "AGE" IS YEARS AFTER CONTRACTING PULMONARY EMBOLISM 
00 
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4. 	POTENTIAL ECONOMIC BENEFITS OF BEOPROCESSING IN SPACE FROM CASE
 
STUDY DISEASE TREATMENT IMPACT
 
The total potential economic benefits of space processing of biological
 
material are beyond the scope of this study, only the benefits that may
 
accrue from the two case studies are discussed here. The case study
 
benefits will be discussed by disease.
 
4.1 	 Estimation of Benefits to ESRD Treatment
 
4.1.1 	 Reduction in Number of Deaths
 
The treatment which was expected to benefit from space processing was kidney
 
transplant treatment. Table 3.2.1 indicates the impact of a reduced expected
 
mortality rate resulted inan expected increase inlife expectancy, or
 
extended years of survival after the onset of ESRD. The optimistic case
 
realized a mean increase of almost four years of life expectancy after
 
onset of ESRD. Thus, if the reduced mortality comes to pass as a result of
 
improved immunology techniques which were affected by space processing the
 
average person contracting ESRD could expect to live 17 years after contracting
 
ESRD, rather than the previously expected 13. The standard deviation for the
 
optimistic case is over 11 years meaning that the person might only live 3
 
more years or last as long as 28 years more. When this extension of life
 
expectancy isexperienced by the 10,000 new ESRD patients, each year the
 
number of reduced annual deaths, or prolonged lives becomes significant.
 
Caution must be used in over projecting the total years of life extension
 
as the age of the patient at the time of contracting ESRD must be considered.
 
4.1.2 	 Increase in Number of Kidney Transplants and Decrease in Rejection
 
Rate of Transplants
 
It is assumed that if lymphocytes can be successfully separated into subgroups
 
that an enhancing antibody can be developed which may significantly decrease
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the 60 percent transplant failure rate caused by the body's rejection.
 
If-this rejection rate decreases, it can be assumed that a significant
 
ihcrease in the number and percent of patients receiving transplants will
 
occur. This is reflected in the probability increase from .20 to .45 in
 
Figures 3.1.6 and 3.1.8 in the transition from first year dialysis to
 
transplant.
 
A concomitant increase in demand to secure sufficient numbers of cadaver
 
kidneys would occur, but this is considered surmountable with improved
 
donor education programs, universal donor cards, and so forth.
 
The increase in the number of people with functioning kidney transplants
 
would yield a healthier population, with a decrease in dependence on
 
machine dialysis.
 
4.1.3 Reduction of Costs from Reduction in Number of Patients on Dialysis
 
Once a successful kidney transplant has occurred, the costs to both the
 
federal government and the private individual decrease due to the lack of
 
a need for medical intervention except for check-ups. Comparing the baseline
 
case with the optimistic case, the model run results shown in Table 3.2.1
 
indicate a reduction of expected discounted individual costs from $73,843
 
to $41,890. These figures are the expected costs incurred during one
 
individual's lifetime. This reduction occurs despite an increase in the
 
number of years for which costs can accrue.
 
The reduction in costs to the government sector is equally dramatic. Again,
 
taking the optimistic case compared to the baseline case, the potential
 
expected discounted reduced government costs for one individual is about
 
$100,000 over a mean 17 years, despite an extended expected longevity.
 
This is in large part due to the lack of government incurred costs for a
 
successfully transplanted ESRD patient.
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To gauge the potential magnitude of benefits possible from reduced government
 
costs in ESRD treatment determined from this preliminary analysis a specific
 
block of time will be examined wherein the baseline case will be compared
 
to the partial improvement and the optimistic case. The time period begins
 
in 1985, the soonest that benefits are expected to begin after the Space
 
Shuttle becomes operational, and extends until the year 2000. The time block
 
is thus 15 years. Costs determined in 1975 dollars were inflated at a 6
 
percent compound interest rate for ten years thus yielding 1985 dollars.
 
Cost streams were then generated for 10,000 patients starting in each of the
 
fifteen years and continuing until the year 2000. These cost streams were
 
generated for the baseline case, the partial improvement case and the
 
optimistic case. Each of the cost streams was discounted back to 1985
 
thus yielding a comparison of discounted cost streams. The total expected
 
government cost for this time block was $12.7 billion ($1985, 10% discount
 
rate) while the partial improvement case was $10.3 billion($1985; 10%
 
discount rate) and the optimistic improvement case costs were $7.2 billion
 
($1985; 10% discount rate). Thus, the total potential cost saving benefit
 
to the government may be between $2 and $5 billion over a 15 year period.
 
These benefits are considered for the U.S. only. Outside the United States
 
where dialysis machines may not be as readily available the benefits may be
 
relatively more substantial, although perhaps predominately to the individual.
 
4.1.4 	 Increase in Benefits to those Surviving Transplantation beyond
 
Normal Rejection Period.
 
If space processing can contribute to developing techniques to reduce kidney
 
transplant rejection, the people realizing such changes would realize several
 
benefits. First would be added years of life. Second would be an opportunity
 
to earn income during the added years for transplant patients are often healthy
 
enough to lead fairly active lives.
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4.1.5 Total Benefits for ESRD Treatment
 
The potential total benefits for ESRD treatment include the extension of
 
life expectancy for ESRD patients and the savings of billions of dollars
 
of costs of alternative treatments which would not be neces-sary if
 
transplant acceptance rates were improved.
 
During a fifteen-year period from 1985 to 2000, an approximate total of
 
150,000 people will be medically suitable for treatment of End Stage Renal
 
Disease. Ithas been determined from the use of the model that on the average
 
a person could live 4 years longer from changes inmedical treatment developed
 
as a result of space processing. If such measures were to come about and were
 
implemented on a wide scale then each of the 150,000 people stands to live
 
4 years longer, on the average. Thus during the life time of these people,
 
which would undoubtedly stretch beyond the 15-year time period, but whose
 
treatment would begin in that period, a total life extension of 600,000
 
man years may be obtained.
 
The potential economic benefit to the government may be $2 to $5 billion
 
($1985; 10% discount rate) over a fifteen year period. The potential benefit
 
to private individuals would be smaller, but significant.
 
4.2 Estimation of Benefits to Pulmonary Embolism Treatment
 
4.2.1 Reduction in Number of Deaths
 
Initial experimentation with urokinase has not yielded any change inmortality.
 
However, indications from foreign users of the drug are that a reduction in
 
mortality may occur. It is for this reason that a decreased probability of
 
death was entered in the transition probability matrix of the partial
 
improvement and optimistic improvement cases. This resulted in a significant
 
increase in the expected life expectancy of a pulmonary embolism patient, 13
 
years in the optimistic case.
 
53
 
4.2.2 Decreased Hospital Stay
 
The one characteristic that urokinase has unquestionably exhibited isthe
 
ability to "clear up" clots within short periods of time. It is anticipated
 
that this will yield reduced mortality. Due to the internal nature of clots
 
and the life-critical nature of the disease, it is not yet clear what test
 
procedures and other procedures can be foregone during the treatment of a
 
pulmonary embolism with urokinase, at present itappears that urokinase will
 
not reduce total hospital stays, but may reduce the need for some expensive
 
procedures like surgery. The price of urokinase may be several thousand dollars
 
for a 4 million unit dose 44 thus offsetting the cost of a more lengthy hospital stay.
 
4.2.3 Reduced Urokinase Production Costs
 
Propriety information prohibits complete exploration of this question.
 
It is known that the cost of one dose of urokinase utilizing the urine
 
extraction technique was about $1,500, the selling price would
 
undoubtedly be considerably higher. The selling price of urokinase outside
 
the United States is similarly high. The cost of urokinase from the tissue
 
culture growth technique is not known.
 
Grant Barlow of Abbott Labs in Chicago has related that less than 5 percent
 
of kidney cells are capable of producing urokinase,45 yet they will have
 
to propagate all of a kidney's cells before they can extract the specific
 
cells they desire. Dr. Barlow has calculated that Abbott Labs would
 
experience decreased production costs if they could effectively fractionate
 
the urokinase producing cells inspace from the other kidney cells prior to
 
propagation, at an estimated cost of $300 or $400 per pound for space processinq.
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Limitations of time and resources as well as limited access to proprietary
 
information have not permitted a thorough analysis of the potential cost
 
reduction. However, a parametric analysis was performed with the model
 
using a 10:1 co't reduction for the price of urokinase. Ifthe expected
 
costs are compared for the first few years, the optimum improvement case
 
proves less expensive. No perceived total expected costs were achieved
 
for the 30-year duration but itmust be recalled that the life expectancy
 
after contracting a pulmonary embolism isvirtually doubled in the optimistic
 
improvement case, and allowing for patients to repeat treatment during that
 
time period, itwould be slightly higher. Inaddition to reduction of urokinase
 
production costs, itappears conceivable that the volume of production may
 
be greater with a space processing segment in the manufacture of the drug
 
due to a comparative reduction in the space needed to grow tissue cultures.
 
4.2.4 Total Benefits for Thromboembolic Disease Treatment
 
The benefits of space processing in the manufacture of urokinase are difficult
 
to determine this early inthe understanding of treatment procedure utilizing
 
urokinase and without more definitive data. Clearly if urokinase can reduce
 
mortality a benefit of longevity would result and increased productivity and
 
income earning potential which would not be possible under present mortality
 
rates. Ifspace processing can reduce costs in the manufacture of the drug,
 
this savings would be passed on to the patient relative to the potential cost
 
of complete ground-based processing. The magnitude of these benefits cannot
 
be measured due to limited access of proprietary information and the need
 
for better clinical data on urokinase efficacy.
 
5.1 
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5. ALTERNATIVE TECHNOLOGY POTENTIALS AND CONCLUSIONS
 
Alternative Technology Potentials
 
Two alternative technologies which appear potentially capable of performing
 
cell separation are the fluorescent-activated cell sorting and affinity
 
chromatography. The first technique utilizes a process whereby certain
 
cells are tagged with fluorescein and then sent through an orifice at a high
 
rate of speed. At the moment that each drop containing a cell.is sent out,
 
an electrical charge is given to the droplet based on predetermined
 
characteristics which are measured with the aid of a laser. The
 
electrically charged cell droplet streams are then pulled into one of
 
several test tubes by passing through an electrical field.
 
The fluorescent-activated cell sorter is available commercially but has not
 
yet undergone use in testing and experimentation necessary to determine
 
whether this apparatus is appropriate for lymphocyte subgroup separation or
 
urokinase producing cell separations. Questions have been raised by the
 
biomedical community 46 regarding cell viability after (and if) the apparatus
 
can successfully perform the separations. Further testing of cell separations
 
using the fluorescent-activated cell sorter will be needed to determine its
 
full potential. Several years of time and large expenditures of funds are
 
needed before determination can be made. Based on discussions with biomedical
 
researchers who are theorizing that electrophoretic separation in space will
 
be successful, the fluorescent-activated cell sorter cannot yet be ruled out
 
as a potential alternative technology.
 
There have been developed affinity chromotography methods, which make use
 
of the property of biospecific absorption, or the affinity of an enzyme for
 
an insolubilized ligand, for the recovery and purification of cells. Both
 
the specificity of initial binding to the insolubilized liquid and the
 
specificity of subsequent elution from this material are key aspects to the
 
success of this technique. These methods can provide a high degree of
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purification, together with high yield, in one rapid step. Some research
 
is underway to determine if cell sorting of lymphocyte subgroups can be
 
made.47 This technique has been successful in separating T from B
 
lymphocytes. 48
 
Several other alternative technology candidates, such as the ultra-centrifuge,
 
have been ruled out based on technical inability to perform the necessary
 
functions. At the time of this writing, no other presently developed
 
alternative technologies are known which can successfully separate large
 
cells. It is conceivable that another technology could be developed before
 
the Shuttle has become a reality.
 
5.2 Conclusions
 
The purpose of this study was to perform a preliminary analysis of the
 
potential benefits that may accrue from space processing of biological
 
materials. Two case studies were chosen, the separation of lymphocyte cells
 
into subgroups, and the fractionation of kidney cells into urokinase
 
producing cells. Both case studies would utilize the technique of
 
eectrophoresis as the specific separation technology in space. Although
 
both case studies would utilize the same separation technique the purpose of
 
the separation is different in each case. In the lymphocyte separation case,
 
it was determined that, if successful, the separation would help further
 
medical research; while urokinase producing cell separation would be a cost
 
reducing production technique. The urokinase case would be a step in the
 
direction of recurring space processing as distinct from space-based
 
experimentation. In performing the preliminary benefit analysis, it was
 
determined that adequate information existed for at least one disease
 
treatment for each of the case studies.
 
While undertaking a systems analysis of the possible treatment modes for the
 
diseases under examination, a model was developed to systematically gather
 
statistics on the potential outcomes of changes in treatment brought about
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by space processing. The model was sufficiently utilized to ascertain
 
that it is a valuable tool in this type of analysis. The question remains,
 
however, whether the information which has been utilized todate is
 
sufficiently accurate to produce valid results. Investigation was not
 
made into the probabilities of a successful space segment outcome, rather
 
the space segment was treated deterministically - as a success.
 
This preliminary benefit analysis did find that within its limited scope,
 
that if the space segment and certain ground-based research and processing
 
are successful, the potential benefits in economic and life-extending
 
measures are quite substantial. The ESRD treatment program presently funded
 
on an 80 percent level by the government would stand to realize drastic cosc
 
reductions. The potential reduction in deaths and human suffering to be
 
gained from space based experimentation, although less quantifiable, would
 
be significant. In the case of pulmonary embolism, a similar life-extension
 
type benefit would stand to be realized, but additionally a possible
 
reduction in the production costs of urokinase would result.
 
The results of this preliminary analysis indicate that the federal government
 
is in a position to benefit from continued support of bioprocessing inspace.
 
Inaddition to the traditional role of government support of high risk
 
development support, the federal government stands to benefit directly in
 
the case of End Stage Renal Disease which may cost the government upwards of
 
one billion dollars per year for ESRD treatment if treatment changes to
 
improve kidney transplant survival are not made.
 
58
 
6. 	RECOMMENDATIONS
 
Because of the magnitude of benefits indicated in this preliminary analysis
 
of bioprocessing inspace from two specific disease treatment applications
 
of one space processing procedure, it is recommended that further research
 
and analysis be conducted on the case studies utilized in this study; namely,
 
the space-based separation of lymphocytes into subgroups and the separation
 
of urokinase producing cells from other kidney cells. In performing this
 
generic task the following subtasks are recommended:
 
a. 	It is recommended that the model developed for analysis of changes in
 
costs and mortality of disease treatments be verified with more definitive
 
data and comparison with actual statistics. Inaddition, the model
 
should be improved to utilize multiple probability transition matrices,
 
each one related to patient age or years since the disease was
 
contracted. Additional patient transition states may be utilized to
 
more discretely define a patient's progress.
 
b. 	Improvement in the data base is needed to permit more accurate benefit 
assessments. The need for improvement in the data base is particularly 
relevant for the urokinase treatment mode. -
More complete information is necessary regarding the technical
 
capabilities of the medical procedures under study. It is recommended
 
that a closer relationship be developed with technical sources in future
 
work of this nature. An example would be for NASA to contract with a
 
pharmaceutical manufacturer for technical information exchange.
 
c. 	That benefit analysis work be performed on other impactable treatments
 
which could potentially result from successful space separation of
 
lymphocytes and urokinase producing cells from kidney cells. Examples
 
of other impacts would be organ transplants other than kidneys inthe
 
case of lymphocyte separation, and other thromboembolic diseases
 
besides pulmonary emboli in the case of urokinase.
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d. 	It is recommended that any future study in the area of treatment
 
alteration benefits as a result of space processing be subjected to
 
a risk analysis. The present study has treated the benefits ina
 
binary fashion, that is either there are no benefits or they are the
 
totals which have been mentioned. What ismore useful to a decision­
making body and to NASA is a probability distribution of a successful
 
outcome.
 
To determine how to best commit assets, decision makers must forecast
 
or guess the future. Uncertainty about the exact course of future
 
events creates risk-fluctuations in the resulting costs, benefits, and
 
cash-flow patterns. Decision making should explicitly take into account
 
these uncertainties, which require the quantification of risk. In
 
conventional analysis, basic input parameters and resulting computed
 
parameters are treated as single-value functions, that is the values
 
are assumed to be known with certainty, when i'n fact they are not.
 
Risk analysis explicitly considers the uncertainty associated with
 
the basic input parameters required for evaluating a venture and
 
determining the resulting risk. Risk ismeasured in terms of the
 
chance that key performance measures, financial and technical, will
 
meet or exceed specified values.
 
The analysis of risk, then, requires adding a third dimension to the
 
dimension of dollars and time of conventional analysis - namely, the
 
dimension of uncertainty. This means that each major input assumption
 
must be described, not just by single estimate, but by an entire range
 
of possible values with an associated likelihood of the variable fall­
ing into various sectors within the range. In other words, the proba­
bility distribution of the key parameters must be specified as uncer­
tainty profiles. Introducing uncertainty to the input parameters gives
 
the derived or computed results an uncertainty dimension (probability
 
density function), which, when replotted yields the risk profile. To
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restate: Uncertainty refers to the chance of the input parameters
 
taking different values. Risk refers to the resulting variability of
 
computed performance parameters. Uncertainty makes space processing
 
a probabilistic quantity. Therefore, benefits of space processing
 
should be characterized by a probability distribution that represents
 
the chance of achieving each of the possible disease treatments.
 
ECON has considerable experience in the application of risk analysis
 
to space technology and has developed several sophisticated computer­
based Mathematical models to perform such analysis.
 
In performing a risk analysis the entire development procedure is
 
modelled from research and development,through the space segment to
 
an operational mode where the new product, in this case new medical
 
products, are marketed. At each of the intermediate steps a
 
probability distribution is attained from experts in the field.
 
Each expert is only consulted on the probable outcome of an event for
 
which he has expertise. The output would be risk profiles of program
 
success for each parameter such as costs, benefits, and new product
 
development success.
 
In addition to the improvement of the benefit analysis of bioprocessing in
 
space, it is suggested that a similar technique be applied to all proposed
 
space processing scientific projects. If each space processing proposal
 
could be evaluated in terms of potential economic payoff, then the scientific
 
proposals could be ranked to provide decision makers with a measure with
 
which to determine usage of a limited resource.
 
In the National Research Council paper on Costs and Benefits of Practical
 
49

Applications of Space Systems , Kelley and others advocate that a cost­
benefit discriminator be utilized to aid in making funding decisions. 
Naturally this would not be the only criteria used by decision makers, but 
it could provide a far more rigorous method for ranking and prioritizing 
proposed projects than presently exists. 
61 
An existing computer program for this purpose has been developed by ECON
 
personnel using public funds 50 . The program evaluates multiple projects,
 
and multiple costs within multiple budget constraints. The methodology
 
has been funded and iscompleted, leaving only the operational use of the
 
software to pursue this analytical and decision-aiding technique.
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310 FORTRAN
 
99 
loo 

101 

102 

10 

20 
125 

130 
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INTEGER YRS(15)TA (8),,Y(8),Z(8),CSCSPNITS(6)
 
REAL P(15,8,8),C(8),CCC10O) ,AVEA(8),SQA(8),AVEZC8),SOZ(E),AVEN,(8)
 
1,SQNY()gAVECC(100),SQCC(100),DUM1q(29)0DUM2(429)OCC(100)AVEDCCC 
2 100)SCDCCC(100), 
3 PROB(8),O(8),OD(100),AVEDO(100),SQDD(IO),DDD(100),AVE'tDO(IO0)9
 
4 SCODO(100)
 
EQUIV4LENCE (DUM1,AVEALP),(DUM1(2),AVEA)(DUIM(1)-AVEZ),
 
1 (DUMl(18),AVENY),C0UMl(26),AVETCC),(OUMI(27),AVEDTC),
 
2 (CUM1(28),AVECC)9CDUl(12),AVEOCC),
 
3 (OUMt(228)IAVETOD)(DUM1(229)tAVEDTO),(DUM1(23O),AVEDD),
 
4 (DU1(330)9AVEDDD)
 
EQUIVALENCE (DUM2,SQALP),(0U2(2),SGA),(DUM2(10),SGZ),
 
1 CDU"'2(18),SQNY),(DUM2(26),SQTCC),(DUM2(27),SQDTCC)v
 
2 (OUM2(28)tSQCC),(DUJ12(128)ISQDCC),
 
3 (DU2(228),SQTDD),(DU2(229).SGDTD)(DUM2(230),SQOD),
 
4 (QUM2(330),SQDDD) 
NS 6 
NSN = NS - I 
NSM2 z NS 2 
DO 99 L=1,29 
DUMi(L) = 0.
 
DUM2(L) = 0.
 
CONTINUE 
READ(8100) NIT
 
FORMAT(I5,FS.3)
 
REA(8i0) MAXYRDISC
 
MXYRPI = MAXYR - 1
 
READ(80l) C
 
FORMAT(8FIO.2)
 
READ(89101) D
 
DO 10 I=z1MAXYR
 
READ(8,Y102) YRS(I),((P(ItJK)K=1,NS)J=ItNS)
 
FORMAT(15/(6F1O.3))
 
IF(I.GT.1) YRS(I) = YRS(I-1) + YRSCI)
 
IF(YRS(I).GE.4AXYR) GO TO 20
 
CONTINUE
 
NI = I 
DO 125 L=lNS 
NITS(I) = 0 
CONTINUE
 
00 200 L=1,NIT
 
DO 130 I=IMXYRM1
 
CCCI) = 0.
 
DCC( I) = 0.
 
DO(I) = 0.
 
DDD(I) = 0.
 
CONTINUE
 
TDD = 0.
 
DTDO = 0.
 
TCC = 0.
 
DTCC = 0.
 
00 22 1=11INS O 
= 4AXYR + 1A() 

NYCI) = 0
 
Z(1) = 0
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22 

25 
30 
150 

153 

155 

CONTINUE
 
M-= 1 
,Z(I} I 
CS = 1 
I= MAT(M-vYRSMAX'YRqdNS) 
X = RAN(135713) 
CSP = NEWST(PtI,CS,X,NINS)
 
A(CSP) = MINO(A(CSP)qM)
 
IF(CSP.EQ.NS) GO TO 150
 
NY(CSP)l = NY(CSP) + 1 
IF(CS.NE.CSP) Z(CSP) = Z(CSP) + 1 
CC(p) = C(CSP)
 
D(M) = D(CSP)

DCC(Y) = C(CSP)*(!.+DISC)**(-(-1)) 
OD0(M) = O(CSP)*(1.+DISC)**(-(M-1))
TCC = TCC- + CC(M)
DTCC = DTCC + DCC(M) 
TO = T O + DO() 
OTDD = D+DD + ODD(M)
 
OTDM + 1
 
CS CSP
 
IF(MCLTMAXYR) 50 TO 30
 
CSP = Ms 
ALPHA = M
 
A(CSP) = M
 
DO 155 IU=,NS
 
IF(I.EO.1) GO TO 153
 
IF(A(I).EQ.YAXYR+I) A(I) = 0 
IF(A(I).EQ.O) Z(I) = 0
 
IF(A(I).NE.O) NITS(I) = NITS(I) + 1 
CONTINUE
 
AVETCC = AVETCC + TCC
 
SQTCC = SQTCC * TCC**2 
AVETOD = AVETOG + TOO
 
SOTOD = SQTDD + TDD**2
 
AVEALP = AVEALP + ALPHA
 
SQALP = SQALP + ALPHA**2
 
AVEDTC = AVEOTC + OTCC
 
SQDTCC = SQOTCC + DTCC**2 
AVEDTD = AVEDTD + DTDD
 
SQDTO = SQDTD-+ OTDD**2
 
00 160 I=14NS
 
AVEA(I) = AVEA(I) + A(I)
 
SQA(I) = SQA(I) + A(I)**2
 
A'EZ(1) = AVEZ(I) + Z(I) 
SQZ(I) = SQZ(I) + Z(I)**2 
AVENY(I) AVENYCI) + NYU)
 
SGNYtI) SQNY(I) + NY(I)**2
 
CONTINUE
 
DO 170 I=IMXYRPt
 
AVEDCC(I) AVEDCC(I) DCC(I)
 
SQOCC(I) SQOCC(I) + DCC(I)**2
 
AVECC(I) = AVECC(I) + CC(I) 
SGCC(I) = SGCC(I) + CC(I)**2 
AVEDOD(I) = AVEDDD(I) + 0DD(I) 
160 
58 
SQDDD(I) = StDDD(I) + ODD(I)*.*2 
AYEDD(1) = AVEDD(I). + DD(I) 
SQ DO I) = SQDD(I)+'DDT(I)L**2 
170 'CONT'INUE 
C WRIT.E(9,6001) (A(I),I=2,NS),Z,(NY(I)gI=NSM2ALPhATCCDTCCTDi 
C I DTDD" 
6001 FORMAT(1913,5F12o2) 
2O0 CONTINUE 
AVEALP = AVEALP/NIT 
SQALP =zS0RT((SQALP-NIT*AVEALP**2)/(NIT-1)) 
DO 250 I=1,NS 
PROe(I) = 1.0*NITS(1)/NIT 
IF(UITS(I).NE.0) AVEA(I) 

IF(NITS(I).GT.1) SOA(I) 

i 1)-i)) 
IF(NITS(I).NE.0) AVEZ(I) 

IF(U ITS(I).GT.1) SOZ(I)

1 )-1))
 
250 CONTINUE 
- 00 300 L=18,429 
DUMI(L) = DUMIHL)/NIT
 
= AVEACi)/NITS(I)
 
= SQRT((SOA(I)-UITS(I)*AVEA(I)*-2)/(NITS(
 
= AVEZ(I)/NITS(I)
 
= SQRT((SQZ(I)-NITS(I)*AVEZ(I)**2)/(NITS(I
 
IF((DUM2(L)-NIT*DUMI(L)**2).LE.O.) GO TO 300
 
DUX2(L) = SQRT((DUM2(L) - NIT*OUM1(L)**2)/(NIT-1))
 
300 CONTINUE
 
WRITE(6,6101)
 
6101 FORMAT(T13,'PRO6. OFt/T139,'ENTERINGt/T3,'STATE',5X, 'STATE'/
 
1 T2,8-(IH*),3X,8(IH*))
 
WRITE(C66102) (JPROB(d)J=1,NSMI)
 
6102 FORMAT(I5,F14.3)
 
WRITE(6,6002)
 
6002 FORMAT(//T27,'STANDARD'/T2,'VARIABLE',6X,'I:AN 7X,*DEVIATION$/
 
1 'X,9(1H*),3X98(1H*),5X,9(1H*)/)
 
WRITE(6,6003) DUMI(1),DUM2(1),(LDUV1(L+1),UM2(L+1),L=2,NSM1),
 
i (LDUMI(L+9),DUM2(L+9),L=1,NSM1),(LDUM1(L+17),OU2(L+17),L=INSl
 
2 I)t(DUM1(L),DUM2(L)qL=26e27)(DUMI(L),DUN2(L) L=228,Z29)
 
6003 FORMAT(' AGE DEATH'iF9.2F14.2//4(t AGE IN SIIF9.2,F14.2/)
 
1 /5(' Z IN S'qI1,F9.2,FI.21)/5(' NYR IN S',I1,F$.2,F14.2/)
 
2 /' TOT COST*,FIO.2,F14.2//' TOT DCOSTtF9.2,FI4.2/
 
3 /' TOT IND C',F5.2,Flq.2//' TOT IND D',F9.2,F14.2/)
 
WRITE(6,6104)
 
6104 FOR 4 AT(//T23'GOVERNMENT COSTS',T93,'INDIVIDUAL COSTS'/
 
1 T2,59(lH*),T72,59(1H*))
 
WRITE(6,6006) DISC,DISC
 
6006 FORMAT(//T41ilDISCOUNTED ATt,E5.2,lT-1,DISCOUNTED'ATlF5.2/T39,
 
1 22(1H*),T109,22(1H*)/)
 
WRITE(G6004)
 
6004 FORMAT(? COST AT'.T27,'STANDARO',T52,OSTANDARD,T72,' COST AT',
 
1 T97,'STANDARD',Tl'22,'STAND'ARD'/
 
1 4x, AGE',T1G,'MEAN',T27,Y'EVIATION,T41,?MEANW T52,'DEVIATION',
 
2 T75,'AGE'T86tFIEAN',T97,'OEVIATION',Tl1,NMEAN',T!22,tDEVIATION'
 
2 /1X,9(IH*),3X,8(1H*),5X,9(IH*),3X,8-(IH*)5X9(lH*)9 1
 
3 T72,9(IH*),3X,StlH*),5X,9(iH*),3XS(1H*),SX,9(IHt)/)
 
WRITE(6,6005) (LtDUMI(L+27),DUM2(L+27) DUM1(L+27+100),DLM2(L+
 
I 27100),L,DUM1(L+229),DUM2(L+229),DUMI(L+229+100),DUM2(L+229+100
 
2 *),L=IMXYRM1)
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2 9 F 4
 
6005. FORMAT(1O (I6,F15.2,F14.2,F ! 1.2 J' 14.2,T719
I6 9F 1 5 2 iF l l. 2
 
1 2"/)/) 
STOP
 
END
 
NEWST FORTRAN
 
FUNCTION NEWST (PI.CS,X ,NINS) 
INTEGER CS 
REAL P(15,8,8) 
Z = 0. 
00 10 J-INS 
Z =Z + P(I-,CS.J) 
IF(Z.-GT.X) 5O TC 20 
10 CONTINUE 
STOP 456 
20 NEWST = J 
RETURN 
END 
MAT FORTRAN
 
FUNCTION MAT(MYRS iAXYRNS)
 
INTEGER YRS(NS)
 
.00 10 ItIiMAXYR
 
IF(M-GT.YRS(CI)GO TO 10
 
GO TO 20 
10 CONTINUE'
 
STOP 123' 
20 MAT = I 
RETURN
 
END
 
0w[! 
RESULTS OF ESRD TREATMENT SIMULATION
 
PARTIAL OPTIMISTIC 
BASELINE IMPROVEMENT IMPROVEMENT 
MEASURE STANDARD STANDARD STANDARD 
MEAN DEVIATION MEAN DEVIATION MEAN DEVIATION 
"AGE" (A)AT DEATH 13.72 10.18 15.05 10.88 17.11 11.44 
"AGE" WHEN ENTERING (FOR FIRST TIME) 
CONTINUING DIALYSIS 1.96 2.90 2.97 4.61 4.07 6.37 
TRANSPLANT 5.27 6.65 4.53 5.31 3.03 3.48 
POST-TRANSPLANT 6.41 6.47 6.72 6.11 4.57 4.15 
NUMBER OF YEARS IN 
CONTINUING DIALYSIS 10.64 9.42 7.00 7.03 3.60 4.78 
TRANSPLANT 0.55 0.90 1.37 1.40 1.55 1.27 
POST-TRANSPLANT 1.14 3.21 4.81 6.62 10.20 9.60 
COST TO PUBLIC SECTOR PER INDIVIDUAL 
OVER INDIVIDUAL'S LIFE ($) 
UNDISCOUNTED 430,262 (365,221) 324,313 (287,594) 195,514 (198,158) 
DISCOUNTED AT 10% 208,280 (132,714) 162,947 (113,368) 108,231 ( 93,147) 
COST TO PRIVATE SECTOR PER INDIVIDUAL ($) 
UNDISCOUNTED 24,371 ( 49,075) 80,859 ( 92,668) 95,597 ( 76,894) 
DISCOUNTED 12,191 ( 22,792) 32,053 ( 34,060) 41,890 ( 34,725) 
(A) THROUGHOUT, "AGE" IS MEANT TO BE YEARS AFTER CONTRACTING ESRD 
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BASELINE CASE ESRD TREATMENT MODEL RUN
 
PROS. OF
 
ENTERING
 
STATE STATE
 
1 1.000 
2 0.841
 
3 0.367 
4 0.193
 
VARIABLE MEAN

***************** 
AGE DEATH 13.72 
AGE IN 32 1.56 
AGE IN $3 5.27 
AGE IN S4 6.41 
Z IN S1 1.39 
Z IN S2 1.16 
Z IN S3 1.45 
Z IN S4 1.20 
NYR IN St 0.39 
NYR IN 32 10.64 
NYR IN 33 0.55 
NYR IN S4 1.14 
TOT COST 430262.75 

:TOT DCOST208280SO50 

TOT IND C151362.12 

STANDARD
 
DEVIATION
 
*****
 
10.18
 
2.90
 
6.65
 
6.47
 
0.70
 
0.42
 
0.80
 
0.49
 
0.70
 
9.42
 
0.90
 
3.21
 
365221.56
 
132714.25
 
126065.50
 
_TOJTII.0.D--D73843 .31 --- 45563.25.
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BASELINE CASE ESRD TREATMENT MODEL RUN
 
COST AT 
AGE MEAN 
1 31424."i 
2 27329.41 
2637r.08 
24845.90 
6 21889.77 
T' 2-1244.67 
3< 20534.59 
9- 19394.22 
10 1814-7'.48 
11 -17018.35 
12 16074.30 
13 15245.00 
14 14131.35 
15 13143.60 
16 12487.50 
17 11733.65 
18 11158.00 
19 10403.35 
20 9438.90 
21 8999.15 
22 8453.55 
23 7904.55 
24 7532.20 
25 7137.60 
26 6746.75 
27 6395.05 
28 6189.40 
29 5711.75 
(con't)
 
GOVERNMENT COSTS
 
STADARD 

DEVIATION 

11808.75 

16406.15 

17202.82 

17845.50 

18583.46 

18594.75 

18691.15 

18793.81 

18741.78 

18722.53 

18565.26 

18525.80 

18286.82 

17939.34 

17755.33 

17464.47 

17205.58 

16616.92 

16307.44 

16076.66 

15716.04 

15319.02 

15049.31 

14743.10 

14457.23 

14173.97 

13974.70 

13537.87 

DISCOUNTED AT 0.10
 
STANDARD
 
MEAN DEVIATION
 
31424.41 11808.75
 
24843.82 14916.66
 
21797.70 14218.75
 
18667.25 13407.04
 
13592.24 11538.76
 
11992.13 10496.45
 
10537.80 9591.57
 
9047.63 8767.62
 
7696.26 7948.44
 
656114 7218.77
 
5633..84 6507.35
 
4857.30 5903.29
 
4093.17 5297.36
 
3461.10 4724.20
 
2989.2" 4250.69
 
2553.49 3800.93
 
2207.44 3404.16
 
1871.07 3024.74
 
1543.28 2666.45
 
1337.64 2389.80
 
1142.34 2123.76
 
971.05 1881.94
 
841.19 1680.72
 
721.61 1496.86
 
622.70 1334.40
 
536.59 1189.31
 
472.12 1065.99
 
396.08 938.79
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BASELINE CASE ESRD TREATMENT MODEL RUN
 
IINDIVIDUAL 

COST AT 
AGE MEAN 
1 11264.70 

2 10483.00 

3 9182.60 

4 8661.90 

5 7979.10 

7619.10 

7 7506.70 

8 7327.50 

9 6692.50 

l0 6461.10 

11 5909.40 

12 5735.30 

13 5294.20 

4
836.30 

15 4576.20 

16 4322.70 

17 4056.60 

18 5898.60 

19 3658.70 

120 3284.10 

21 3154.10 

.22 2947.20 

23 2770.10 

24 2628.30 

25 2447.40 

26 2339.20 

27 2215.30 

28 2155.20 

i29 1959.60 

(con't)
 
COSTS 
STANDARD 

DEVIATION 

3677.38 

7514.22 

6449.14 

6690.16 

6612.30 

6874.86 

6995.94 

7135.12 

6715.09 

7046.80 

6735.37 

6953.88 

6665.16 

6420.40 

6442.09 

6340.68 

6213.63 

6217.87 

6111.66 

5828.50 

5833.97 

5638.40 

5524.17 

5391.90 

5185.55 

5142.12 

5044.25 

4986.91 

4731.37 

DISCOUNTED AT 0.10 
STANDARD 
MEAN DEVIATION 
1126 .70 3677.38 
9529.65 6830.21 
7588.#39 5329.93 
6507.37 5027.05 
5449.65 4516.45 
4730.53 4269.07 
4237.03 3949.30 
3760.10 3661.531 
3122.07 3132.76 
2740.10 2988.53 
2278.24 2596.85 
2010.12 2437.31 
1686.81 2123.71 
1400.84 1859.83 
1205.04 1696.45 
1034.83 1517.93 
882.83 1352.30 
771.32 1230.20 
658.05 1099.24 
536.98 953.02 
468.83 867.201 
398.26 761.93 
340.29 678.63 
293.52 602.17 
248.48 526.48 
215.90 474.61 
185.87 423.25 
164.39 380.40 
135.88 328.10 
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PARTIAL IMPROVEMENT CASE ESRD TREATMENT MODEL RUN
 
STATE 

1 
2 
3 

4 

VARIABLE 

AGE DEATH 

AGE IN S2 

AGE IN S3 
AGE IN S4 
Z IN Si 
Z IN 82 
Z IN S3 
Z IN S4 
NYR IN Si 

NYR IN 32 

NYR IN S3 

NYR IN S4 

PROB OF
 
ENTERING
 
STATE
 
-1.0.00. 
0.799
 
0.662
 
0.522
 
MEADEVIATION
 
15.05 

2.97 

4.53 

6.72 
1.88 

1.43 
1.99 

1.56 
0.88 

7O0 

1.37 

4.81 

STANDARD
 
10.88
 
4.61
 
5.31
 
6.11 
1.05
 
0.65 
1.15
 
-0.80 
1.05
 
7.03
 
1.40
 
6.62
 
TOT COST 324513.06 

TOT DCOST162947.12 

TOT INO C124584.00 

TOT IND D 62246.61 

287594.44
 
113368.25
 
107105.00
 
41116.11
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PARTIAL IMPROVEMENT CASE ESRD TREATMENT MODEL RUN
 
(con't) 
INDIVIDUAL COSTS 
DISCOUNTED AT 0*10 
COST AT STANDARD STANDARD 
AGE MEAN DEVIATION MEAN DEVIATION 
1 11204.40 3580.84 11204.40 3580.84 
2 9588.50 8305.97 8716.*45 7550.25 
3 8129.00 73'17.29 6717.72 6047.57 
4 7066.00 7596.84 5308.37 5708.11 
5 6463.20 7656.23 4414.24 5229.54 
6 6053.70 7766.80 3758.62 4822.79 
7 5686.30 7692.17 3209.56 4342.19 
8 5550.20 7789.75 2848.04 3997.48 
9 5135.10 7500.59 2395.42 3499.16 
10 4536.40 7165.77 1923.83 3038.97 
4207.80 7105.16 1622.25 2739.35 
12 4271.10 7368.67 1496.93 2582.68 
13 3884.30 6957.16 1237.63 2216.75 
14 
15 
3698.00 
3546.00 
6944.67 
6754.34 
1071.17 
933.78 
2011.63 
1778.67 
16 3637.40 6991.52 870.76 1673.74 
17 
18 
19 
3567.60 
3254.50 
3188.50 
6984.58 
6470.23 
6658.04 
776.41 
643.89 
573.48 
1520.08 
1280.12 
1197.52 
20 2692.80 6059.45 440.29 990.78 
21 2713.40 6042.89 403.32 898.25 
22 2459.20 5898.44 332.32 797.07 
23 
24 
2360.90 
2238.20 
5790.98 
5654.12 
290.03 
249.05 
711.40 
631.45 
25 
26 
2175.60 
1937.00 
5829.69 
5220.46 
220.88 
178.77 
591.87 
481.85 
27 1895.90 5552.94 159.07 465.93 
28 
29 
1816090 
1630.70 
5188.61 
4907.82 
138.59 
113.08 
395.79 
340.34 
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PARTIAL IMPROVEMENT CASE ESRD TREATMENT MODEL RUN
 
CUST AT 
AGE MEAN 
1 30072.37 
2 23760.34 
3 21970.83 
4 19044.59 
5 17144.9q 
6 1578S.25 
7 14819.20 
8 14327.75 
9 13314.90 
10 12042.70 
11 11069.65 
12 10794.75 
13 10146.50 
14 9516.00 
15 9232.50 
16 9136.85 
17 8882.10 
18 8446.50 
19 7922.85 
20 7202.05 
21 7054.85 
22 6447.40 
23 6189.50 
24 5759.35 
25 5357.50 
26 5124.95 
27 4738.55 
28 4685.20 
29 4337.70 
(con't)
 
GOV-ERNNENT COSTS
 
STANDARD 

DEVIATION 

11663.35 

17294.28 

17791.04 

18249.37 

18101.12 

17932.39 

17771.90 

17744.23 

17363.09 

17021.76 

16651.03 

16496.03 

16225.37 

15899.63 

15748.29 

15661.93 

15533.33 

15217.72 

14833.67 

14532.79 

14229.56 

13856.48 

13626.50 

13097.53 

12749.34 

12514.00 

12227.47 

12055.23 

11706.17 

DISCOUNTED AT 0.10
 
MEAN 

30072.37 

21599.61 

18157.45 

14308.48 

11710.26 

9801.93 

8364.83 

7352.39 

6211.41 

5107.19 

4267.70 

3783.43 

3232.87 

2756.35 

2431.19 

2187.19 

1932.95 

1671.04 

1424.97 

1177.58 

1048,57 

871.25 

760.36 

643.20 

543.93 

473.02 

397.60 

357.38 

300.0 

STANDARD 
DEVIATION
 
11663.35
 
15723.11
 
14703.90
 
13710.731
 
12363.45:
 
11134.94'
 
10032.13
 
9105.89
 
8100.25
 
7219.11
 
6420.02
 
5781.93
 
5170.11
 
4605.75
 
4147.16
 
3749.47
 
3380.60
 
3010.82
 
2668.02
 
2376.27
 
2115.20
 
1872.50
 
1674.02
 
1462.76
 
1294.43
 
1155.04
 
1025.98
 
919.57
 
811.77'
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OPTIMISTIC IMPROVEMENT CASE ESRD TREATMENT MODEL RUN
 
STATE 
PROB.- OF 
ENTERING 
STATE 
1 
2 
3 
4 
1.000 
0.603­
0.777 
0.692 
VARIABLE MEAN 
STANDARD 
DEVIATION 
AGE DEATH 17.11 11.44 
AGE IN S2 
AGE IN S3 
AGE IN S4 
4.07 
3.03 
4.57 -
6.37 
3.48 
4.15 
Z 
Z 
z 
z 
IN S 
IN 32 
IN S3 
IN s4 
1.77 
1.26 
1.97 
1.68 
0.94 
0.52 
1.06 
0.83 
NYR 
NYR 
NYR 
NYR 
IN S1 
I N S2 
IN S3 
IN 34, 
0:77 
3.60 
1.55 
10.20 
0.94 
4:78 
1.27 
9.60 
TOT COST 195514.44 198158.37 
TOT DCOST108231.06 93147.81 
TOT IND C 75597.00 76894.37 
TO T IND D 41890.05 34725.24 
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OPTIMISTIC IMPROVEMENT CASE ESRD TREATMENT MODEL RUN
 
COST AT 
AGE MEAN 
1 27293.64 
2 17347.50 
3 1i839.40 
4 12166.25 
5 10856.50 
6 9432.95 
7 8440.35 
8 8035.30 
9 7066.75 
10 C312.65 
11 5803.15 
12 5810.95 
13 5304.65 
14 5106.30 
15 4670.45 
16 4394.00 
17 4554.90 
18 4175.55 
19 3761.95 
120 3538.30 
21 3356.45 
22 3233.65 
23 3213.20 
24 2955.85 
25 2834.65 
26 2719.45 
27 2739.30 
28 2907.60 
29 2647.05 
(can't)
 
GOVERNMENT COSTS
 
STANDARD 

DEVIATION 

11827.17 

17839.93 

17470.30 

16992.62 

16202.31 

15435.25 

14936.42 

14572.37 

13986.60 

13336.60 

12916.30 

12834.09 

12533.68 

12257.97 

11744.10 

11414.09 

11459.06 

11121.A5 

10656.96 

10396.12 

10165.82 

10007.90 

9768.79 

9438.60 

9368.74 

9275.57 

9281.95 

9640.32 

9083.07 

DISCOUNTED AT 0.10 
MEAN 
STANDARC 
DEVIATION 
27293.64 
15770.20 
12263.61 
9140.52 
11827.17 
16218.40 
14438.70 
12766.76 
7415.12 
5857.05 
4764.25 
4123.37 
3296.65 
2677.14 
11066.48 
9584.29 
8431.41 
7478.15 
6525.02 
5656.15 
2237.31 
2036.69 
1690,20 
1479.10 
1229.68 
1051.90 
991.29 
825.12 
676.63 
578.54 
4979.95 
4498.37 
3993.70 
3550.78 
3092.66 
2732.49 
2493.86 
2200.44 
1916.80 
1700.03 
498.92 
436.97 
394.73 
330.11 
287.79 
251.00 
229.85 
221.79 
183.56 
1511.12 
1352.41 
1200.0h 
1054.11 
951.19 
856.12 
778.82 
735.36 
629.86 
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OPTIMISTIC IMPROVEMENT CASE ESRD TREATMENT MODEL RUN
 
(con't) 
INDIVIDUAL COSTS 
DISCOUNTED AT 0.10 
COST AT STANDARD STANDARD 
AGE MEAN DEVIATION MEAN DEVIATION 
1 10831.20 3805,66 10831.20 3805.66 
2 6962.70 8456.31 6329.31 7687.51 
3 5348.90 7133.95 4420.25 5896.26 
4 4490.50 7468.18 3373.39 5611.20 
5 
6 
4099.60 
3691.10 
7283.37 
7330.34 
2799.90 
2291..72 
4974.72 
4551.61 
7 3385.40 7404.24 1910.90 4179.54 
8 
9 
10 
3184.30 
2615.30 
2398.50 
7097.60 
6459.08 
'6429.46 
1633.99 
1220.02 
1017.20 
3542.23 
3013. 23 
2726.66 
11 2240.00 6394.54 863.62 2465.37 
12 2242.70 6270.40 786,04 2197.74 
13 1974.90 6038.06 629.25 1923.96 
14 2015.20 6214.00 583.72 1800.01 
15 1762.20 5732.28 464.04 1509.52 
16 1751.80 5891.10 419.36 1410.31 
17 1953.60 6216.49 425.16 1352.90 
18 1545.90 5328.69 305.85 1054.26 
19 1507.10 5599.98 271.07 1007.22 
20 1304.80 5096.53 213.34 833.33 
21 1283.00 5194.12 190.70 772.07 
22 1243.40 5145.73 168.02 695.34 
23 1312.20 5218.81 161.20 641.11 
24 1234.30 5230.75 137.84 584.17 
.25 1142.30 5057.06 115.97 513.44 
26 1016.00 4701.83 93.77 433.98 
27 1071.80 4830.21 89.53 405.30 
28 1109.20 4817.54 84.61 367.48 
29 882.90 4010.74 61.22 278.13 
MEASURE 

"AGE"* AT DEATH 

PROBABILITY OF ENTERING
 
STATE
 
HEPARIN 

SURGERY 

UROKINASE 

POST-TREATMENT 

NUMBER OF YEARS IN
 
'HEPARIN 

SURGERY 

UROKINASE 

POST-TREATMENT 

COST TO PRIVATE INDIVIDUALC$) 

RESULTS OF THROMBOEMBOLIC TREATMENT SIMULATION 
BASELINE IN . HPRQVEME _ PAR. IMPROVEMENT OPT. IMPROVEMENT 
CASE CASE CASE .. CASE 
STAN. STAN. STAN. STAN. 
MEAN DEV. MEAN DEV. MEAN DEV. MEAN DEV. 
17.42 10.98 17.11 11.02 21.64 17.88 30.79 18.17 
.98 .53 .30 .39 
.34 .22 .28 .26 
.00 .74 .81 .91 
.89 .88 .88 .94 
1.98 1.38 .79 .90 .45 .78 .53 .77 
0.42 .64 .25 .50 .31 .53 .33 .59 
0.00 0.00 1.41 1.16 2.18 2.01 2.88 2.00 
12.43 9.16 12.07 9.06 15.71 14.48 23.62 15.19 
12,933. 8442. 14,560 9836. 17,974 14,626 20,021 12,299. 
*"AGE" IS YEARS AFTER CONTRACTING PULMONARY EMBOLISM
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Baseline Case Pulmonary Embolism Model Run Results
 
-- OF
FFOB. 

• ," '-*"EITEPAIH, 
-SIATE

: . * *.'- . "*., *:-.4: n 
I.I I J2.2 
UAFZtABLE MlEAN 
~****~+$+.***vw
 
AGE DEATH . 16.80 

AGE IM 6 . 76 
''
 hu - u- -. 

-AGE tWSW LL 00c 
AGE Il S5 2.15 
N 1 4 

IN S2 2.62 

Z IN:'3 " 1.14 

Z -IN S4 0.' 

S.I so- ;004 
tt/F: IN 'S. 1. 
NYR 1H13 1.65-
HYR IN S3 G.32 

N'?R I N SY 0 .0 

"UI: S. W.26
-5 
TOT COST "0.0 
TOT DCiJST c.0 

TOT IND C-1223.53... 
T*T " 2 . ­
"TANDARD
 
DE'i ATI OMi 
11.2$
 
2.-3 
-, 
c 
'J40
 
1-220
 
1.07 
005
 
0.0 
1.41 
13 
1. 2? 
0.55 
0.
 
- 9"5
 
0 ., 
0.3 
830,1 .03 
:3D'i. 0-38 01 
ThIO :~­"~ 
~ Ijr 1 1w 3 oi{,~~p 
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- ; 1)-DIjUL :O:TS 
F,TiiIS ,INTED I A: 
COST AT :TIIIDARD STANDARDAGE MEAN )1 MEANDEUIATTIr DF'J PT TOi 
1 .46,.1Q33 20..03. P7'20051­
.~J.7%0.7----1~1 . H5.87' 19E2.12 
.386.80 326 WK.%UC-C'.:-6 - " f"13.214,9t .$ i.6 fl+- !'+.4 1 2C, 
41.F.+t." 7> 1491.9 U17.819 . 0--,.I. 
r. ni..,J itt' "c-ic, ,,.: 
* -- 457.60. 1558.14 45.6 8.ti-nTh55il 
277.2, 1211.49 277.' 1211. ,9
258.93 1173.50 W.97,Cf 1177.3' 
_ 25,a.93 1173.50. !8 ? 173.5C, 
** 3 3 1H 25.8Q 1 .0 . 
I"" a92.... 12 3. 2? .2 Q ... ,14, -14%33 905.20 19.31 92 . ,

.15 I-f 6,-U1. 3 14+- 88.74
884 34 ''j 

1?- 305.a7? V291-010 305.07 12 1 .01-1 
is335.20 1331.04 335.2G 1331. OH
 
1? 222.40 222.4kQ?.E
-1092.65 

', 
-0. 1 + .F'ro f -' i'i-.EA - I-. ' ,," ".,,225.60 1109. S7 22.0ili7
 
2.155.23 945.50 3W795.50o
 
'2 1(1.53 1084.0l4 21; , 108u.04
 
23 212.13 ib.9 262.13 il?8.99c
 
24 -9.2 1040.23 i92127 W0,23
 
ORIGIAL DAGon IS 
Op POOR QrJAl~rly 
84 
Initial Improvement Case Pulmonary Embolism Model Run Results
 
PROB. OF
 
ENTERING
 
STATE STATE
 
1 1.000
 
2 0.530
 
3 0.220
 
4 0.740
 
5 0.880
 
STANDARD
 
VARIABLE MEAN DEVIATION
 
AGE DEATH 17.11 11.02
 
AGE IN S2 4.36 5.57
 
AGE IN S3 9.50 8.81
 
AGE IN S4 4.49 6.84
 
AGE IN S5 2.19 0.40
 
Z IN S1 2.41 1.25 
z IN S2 1.42 0.60 
Z IN S3 1.14 C.35 
Z IN S4 1.76 0.81 
Z IN S5 2.09 1.10 
NYR IN S1 1.59 1.30
 
NYR IN S2 0.79 0.90
 
NYR IN S3 0.25 0*50
 
NYR IN SA 1.41 1.16
 
NYR IN 35 12.07 9.06
 
TOT COST 0.0 0.0
 
TOT DCOST 0.0 0.0
 
TOT IND C 14356.90 9748.48
 
TOT IND 0 14356.90 9748.48
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Initial Improvement Case Pulmonary Embolism Model Run Results (continued)
 
INDIVIDUAL COSTS 
DISCOUNTED AT 0.0 
COST AT STANDARD STANDARD 
AGE MEAN DEVIATION MEAN DEVIATION 
1 5046.10 1977.19 5046.10 1977.19 
2 1078.70 2317.42 1078.70 2317.42 
3 0.0 0.0 0.0 0.0 
4 283.80 1244.46 283.80 1244.46 
5 527.10 1688.37 527.10 1688.37 
6 477.40 1628.53 477.40 1628.53 
7 587.00 1772,27 587.00 177'2.27 
8 303.20 1328.95 303.20-f 1328.95 
9 358.00 1425.78 358.00 1425.78 
10 293.60 1286.97 293.60 1286.97 
11 348.20 1387.98 348.20 1387.98 
12 582.10 1757.85 582.10 1757.85 
13 412,80 1514.43 412.80 1514.47 
14 224.10 1104.22 224.10 1104.22 
15 54.80 548.00 54.80 548.CO 
16 343.50 1367.79 343.50 1367.79 
17 353.30 1406.17 353.30 1406.17 
18 417.50 1532.48 417.50 1532.48 
19 243.50 1199.61 243.50 1199,61 
20 283.80 1244.46 283.80 1244.46 
21 233.90 1152.43 233.90 1152.43 
22 179.10 1023.54 179.10 1023.54 
23 298.30 1308.59 298.30 1308.59 
24 233.90 1152.43 233.90 1152.43 
25 307.90 1349.86 307.90 1349.86 
26 229.00 1128059 229.00 112B.59 
27 59.70 597.00. 59.70 597.00 
28 233.90 1152.43 233.90 1152.43 
29 362.70 1445.11 362.70 1445.11 
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Partial Improvement Case Pulmonary Embolism Model Run Results
 
STATE 
PROB. OF 
ENTERING 
STATE 
1 
2 
3 
4 
5 
1.000 
0.300 
0.280 
0.810 
0.880 
VARIABLE MEAN 
STANDARD 
DEVIATION 
AGE DEATH 21.64 17.88 
AGE IN S2 
AGE IN S3 
AGE IN 84 
AGE IN S5 
8.23 
11.25 
2.95 
2.24 
10.68 
13.05 
5.31 
0.59 
Z 
Z 
,Z 
Z 
Z 
IN S1 
IN S2 
IN S3 
IN S4 
IN S5 
2.83 
1.33 
1.11 
2.51 
2.66 
1.86 
0.55 
0.31 
1.65 
1.86 
NYR IN S1 
NYR IN 82 
NYR IN 33 
NYR IN S4 
NYR IN S5 
1.99 
C.a5 
0.31 
2.18 
15.71 
1.97 
0.78 
0.53 
2.01 
14.48 
H. 
TOT COST .0.0 0.0 
TOT DCOST 0.0 0.0 
TOT IND C 17477.00 14151.62 
TOT INO D 17477.00 14151.62 
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INDIVIDUAL COSTS
 
DIS'COUNTED AT 0..O
 
COST AT STANDARD STANOARD 
AGE MEAN DEVIATION MEAN DEVIATION 
1 5038.80 2138.64 5038.80 2138.64 
2 1054.40 2266.54 1054.40 2266.54 
3 119.20 841.37 119.20 841.37 
4 243.50 1199.61 243.50 1199.61 
5 482.10 1645.13 482.10 1645.13 
6 427.30 1566.35 427.30 1566.35 
7 596.80 1800.71 596.80 1800.71 
8 238.60 1176.76 238.60 1176.76 
9 472.70 1611.74 472.70 1611.74 
10 358.20 1424.94 358.20 1424.94 
417.90 1530.90 417.90 1530.90 
12 472.70 1611'.74 472.70 1611.74 
13 362.70 1445.11 362.70 1445.11 
14 0.0 0.0 0.0 0.0 
15 119.40 840.01 119.40 840.01 
i6 174.20 996.34 174*20 996.34 
17 288.70 1265.90 288.70 1265.90 
18 596.80 1800.71 596.80 1800.71 
19 303.20 1328.95 303.20 1328.95 
20 298.10 1309.49 298,10 1309.49 
21 472.70 1611.74 472.70 1 61 1.7a 
22 298.50 1307.G9 298.50 1307.69 
23 119.40 840.01 119.40 840.01 
24 179.10 1023.54 179.10 1023.54 
25 175.10 1023.54 179.10 1023.54 
26 124.10 873.72 124.10 R73.72 
27 59.70 597.00 59.70 597.00 
28 413.0Q 1513.64 413.00 1513.64 
29 358.00 1425.78 358.00 1425.78 
30 183.80 1051.10 183.80 1051.10 
31 353.30 140G.17 353.30 1406.17 
32 59.70 597.00 59.70 597.00 
33 229.00 1128.59 229.00 1128.59 
34 183.80 1051.10 183.80 1051.10 
35 238.80 1175.77 238.80 1175.77 
36 179.10 1023.54 179.10 1023.54 
37 59.70 597.00 59.70 597.00 
38 114.50 806.29 114.50 806.29 
39 119.40 840.01 119.40 840.01 
40 179.10 1023.54 179.10 1023.54 
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Optimistic Improvement Case Pulmonary-Embolism Treatment Model Run
 
STATE 

1 
2 
3 
4 
5 
VARIABLE 

AGE DEATH 

AGE IN S2 

AGE IN S3 

AGE IN S4 

AGE IN 55 

Z IN S! 
Z IN 32 
Z IN 53 
z IN 34 
Z IN 85 
NYR IN Si 

NYR IN S2 

NYR IN 33 

NYR IN S4 

NYR IN 35 

TOT COST 

TOT DCOST 

'PROB. OF
 
ENTE 0 ING 
STATE
 
1.000 
0.390 
0.268 
0.914 
0.946 
MEAN 

30.79 

13.35 

13.64 

3.15 

2.15 

3.37 

1.30 

1.18 

2.95 

3.30 

2.43 

0.53 

0.33 

2.88 

23.62 

0.0 

0.0 

TOT IND C 16963.48 

TOT IND 0 16963.48 

STANDARD
 
DEVIATION
 
18.17
 
14.4$
 
14.28
 
6.18
 
0.42
 
1.90
 
0.57
 
0.42
 
1.69
 
1.84 
1.95
 
0.77
 
0.59
 
2.00
 
15.19
 
0.0
 
0.0
 
10461.00
 
10461.00
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INDIVIDUAL COSTS 
DISCOUNTED' AT 0.0 
COST AT STANDARD STANDARD 
AGE MEAN DEVIATION MEAN DEVIATION 
1 4321.96 1194.91 4321.96 1194.91 
2 706.96 1781.29 706.96 1781.29 
3 57.16 528.80 57.16 528.80 
4 414.48 1304.11 414.48 1304.11 
5 379.76 1294.56 379.7G 1294.56 
6 382.64 1304.50 382.64 1364.50 
7 426.80 1326.67 426080 1326.67 
8 305.68 1151.24 305.68 1151.24 
9 314.20 1139.54 314.20 1130.54 
10 342.84 1214.08 342.84 1214.08 
11 403.44 1324.01 403.44 1324.01 
12 336.28 1210.30 336.28 1210.30 
13 462.80 1376.01 462.80 1376.01 
14 219.08 967.57 219.08 967.57 
15 287.76 1138.60 287.76 1138.60 
16 299.36 1122.37 299.36 1122.37 
17 393.00 1341.10 393.00 1341.10 
18 339.60 1182.52 339.60 1182.52 
19 279.36 1077.58 279.36 1077.59 
20 235.56 1067o45 235.56 1067.45 
21 318.00 1177.87 318.00 1177.87 
22 292.80 1118.02 292.80 1118.02 
23 279.12 1103,25 279.12 1103.25 
24 257.16 1074.23 257.16 1074.23 
25 360.20 1219.83 360.20 1219.83 
26 272.56 1098.71 272.56 1098.71 
27 178.84 887.59 178.84 887.59 
28 230.60 1021.37 230.60 1021.37 
29 206.56 953.00 206.56 953.00 
30 U35.16 924.66 185.16 924.66 
31 242.32 1055.18 242.32 1055.18 
32 253.36 1031,83 253.36 1031.83 
33 145.72 813.14 145.72 813.14 
34 164.80 837.98 164.80 837.98 
35 
36 
182,64 
160.32 
936.85 
872,10 
182.64 
160.32 
935.85 
872.1.0 
37 178.84 887.59 178.84 887.59 
38 150.32 841.79 150.32 841.79 
39 110.52 679.95 110.52 679.95 
40 192.88 934.37 192.88 934.37 
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APPENDIX C
 
Patient and Government Cost Breakdown
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PUBLIC SECTOR COSTS 
DIALYSIS First Year 
80% of Hospital costs after 3 months 
80% of Doctors' fees 
20% of patients on welfare 
$13,500.00 
1,700.00 
1,000.00 
$16,200.00 
Subsequent Years 
80% of Hospital costs 
80% of Doctors' fees 
20% of patients on welfare 
$18,000.00 
2,300.00 
1,000.00 
$21,300.00 
TRANSPLANT First Year 
80% of Transplant operation 
(see transplant cost breakdown) 
$13,000.00 
Subsequent Years -0-
DEATHS -0­
92 
PRIVATE SECTOR COSTS
 
DIALYSIS First Year 
Center dialysis cost-$17,000 times 70% = $11,900 
(see Center Dialysis Cost Breakdown) 
Home Dialysis- 18,450 times 30% = 5,535 
(see Home Dialysis Cost Breakdown) 
Average. $17,435 
minus income (see income breakdown) 2,200 
$15,235 
Rounded = $15,250/year 
Subsequent Years 
Center dialysis cost $11,850 x 70% = $ 8,295 
Home dialysis cost $8,450 x 30% = 2,535 
$10,830
 
minus income 3,750 
$ 7,080 
Rounded = $ 7,100/year 
93 
TRANSPLANT 
First Year 
20% of average operation cost plus 
other incurred costs 
minus income 
Rounded = 
$9,250 
2,800 
$6,450 
$6,500 
Subsequent Years 
Costs 
minus income 
$5,100 
5,600 
-$ 500 
DEATH 
Estimated Burial Costs $2,500 
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CENTER DIALYSIS COST BREAKDOWN Cs)
 
Surgery for connection 

Counseling (50% assuming $1500/year) 

Changes in diet 

Job loss 

Retraining 

Tutoring 

Diet supplements 

Moving expenses 

Spouse or family job loss or reduction 

Transportation costs 

Dialysis
 
3 month initial period 

Medicare coverage (80%) 

M.D.
 
3 month initial period 

Medicare coverage (80%) 

Ist Year 2nd Year
 
500 0
 
750 150
 
200 200
 
4800 3000
 
500 0
 
150 150
 
250 250
 
250 0
 
1000 750
 
750 750
 
1300 ­
4500 6000
 
750 ­
430 600
 
17,000 11,850
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HOME DIALYSIS COST BREAKDOWN ($) 
1st Year Subsequent Years
 
Loss of spouse work 500 
 500
 
Chair 
 250 -

Plumbing 400
 
Water 600 600
 
Utilities 100 100
 
Training 4000
 
M.D. 800
 
Machine 4000
 
Maintenance 300 300
 
Lab 350 350
 
Hospital Backup 3000 3000
 
Counseling 500 350
 
Diet changes 200 200
 
Job loss 1000 1000
 
Retraining 500
 
Tutoring 100 100
 
Diet supplements 250 250
 
Spouse or family job loss 1000 
 1000
 
600
M.D. 600 

18,450 8,450
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COSTS ($) 
Post Transplant 
TRANSPLANT Ist Year Years 
From living person (30% of total x $14,000)
 
From cadaver (70% of total x $12,800)
 
Average cost of operation to patient
 
(20% of total cost) 	 2600
 
Work loss 	 1800
 
1300
Donor work loss 

Medication and M.D.s 1500 3500
 
Diet changes 200 200
 
Counseling 500 300
 
Tutoring 100 100
 
250
Diet Supplements 

Job decrease (too weak, cannot continue
 
old skill) 1000 1000
 
9,250 5,100
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INCOME
 
Assumptions
 
* Yearly average inc6me estimated at $10,500.00 
* 75% of the male population are of income age. 
* 65% of the female population are of income age. 
* 50% of the female population of income age are in the labor market. 
* Children do not have incomes. 
* Children are designated as those persons under age twenty. 
* 5% of ESRD patients are children. 
First Year Dialysis $2200/year
 
Continued Dialysis $3750/year
 
First Year Transplant $2800/year
 
Post Transplant $5600/year
 
Death $0/year
 
98
 
Estimated Costs of Alternative Treatment
 
Regimes for Pulmonary Embolism
 
ITEM 
Hospital Room 
.-Intensive Care 
Heparin 
Costs in Dollars 
Surgery & 
Heparin 
Normal 
Urokinase 
& Heparin 
Optimistic 
@ $400./day 5 days 
.00 
4 days 
.00 
4 days 
$1600.00 
2 days 
$ 800.00 
. Medium Care 
@ $140./day 
9 days 
$1260.00 
10 days 
$1400.00 
. Semi-Private 
@ $110./day 
- 2 days 
$220.00 
10 days 
$1100.00 
12 days 
$1320.00 
Medication 
. Urokinase - Iday 
@ $2000./day 
$2000.00 
1 day 
@ $200.00/day 
$200.00 
* Heparin $20.00 $20.00 
Physician 
.Surgeon - $1900.00 
. Internist $1500.00 $500.00 $1000.00 $1000.00 
Misc. 
. Misc. Tests & 
X-Rays 
$200.00 $200.00 $200.00 $200.00 
. Lung Scans $600.00 $600.00 $600.00 $600.00 
TOTAL $5580.00 $6440.00 $5970.00 $4140.00 
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